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General introduction 
 
Glaucoma is a progressive neurodegerative disease characterized by optic neuropathy 
and progressive visual field defects in which elevated intraocular pressure (IOP) is 
regarded as the major risk factor.
1-2 Other risk factors that have been consistently 
reported in the literature include age,
3-5 race,
 6-9 family history,
10-12 myopia
13-15 and 
central corneal thickness.
16-18 Because IOP is – thus far - the only modifiable risk factor, 
therapeutic strategies are majorly targeted towards IOP reduction as a protective 
measure against optic nerve damage. However, elevated IOP alone cannot explain all 
observations. Glaucomatous damage can progress after IOP lowering, can also occur with 
normal IOP (normal tension glaucoma; NTG), and the IOP can also increase without any 
signs or damage to the visual field (ocular hypertension).
19-22 There is growing evidence 
in the literature that impaired blood flow and neuroprotection may also play an important 
role in the pathogenesis of glaucoma.
23-26 
 
Although there are several clinical presentations of glaucoma, the two most important 
variants are the open-angle glaucoma (OAG) and the angle closure glaucoma (ACG). This 
classification is based on the anatomy of the anterior chamber angle of the eye as viewed 
by gonioscopy. OAG is the most common form of glaucoma in the western world and the 
studies presented in this thesis are focused primarily on OAG. In OAG, there is an 
increased outflow resistance at the level of the trabecular meshwork resulting in an 
imbalance between the production and outflow of the aqueous humor – with an increase 
in IOP as the result. OAG affects about 45 million people worldwide and this number is 
expected to increase to approximately 59 million by the year 2020.
27-28 Because of the 
insidious nature of this disease, only half of the people with OAG in the developed 
countries are likely to be known to the healthcare system while the number is expected 
to be less for developing countries.
29 With the ageing population, OAG will eventually 
lead to increased medical consumption and costs. 
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In the United States, the total annual cost of therapeutic management of glaucoma is 
estimated to be nearly $2.5 billion.
30 In order to reduce the health burden of OAG, 
effective public health measures should be put in place. Before embarking on public 
health programs, knowledge of the risk factors is important for promoting awareness for 
prevention and early detection of OAG. Furthermore, a good understanding of these risk 
factors could facilitate the treatment and management of the progression of 
glaucomatous visual field loss – and help to unravel its pathophysiology. 
 
The research presented in this thesis was designed to decipher the effect of some 
systemic medications and some other risk factors of OAG. The studies presented in the 
first three chapters are based on the Rotterdam Study, a prospective population-based 
cohort study of age related disorders in the elderly. Our study population comprised of 
3939 of the original 7983 participants aged 55 years and older from the Rotterdam study. 
In chapter 1 we studied whether the use of cholesterol-lowering drugs is associated with 
a reduced risk of OAG. In chapter 2 we explored the association between corticosteroid 
use and incident OAG. In chapter 3 we studied whether antithrombotics could reduce 
the risk of OAG. 
 
The central theme of chapters 4, 5 and 6 is the use of statistical methodology, 
systematic review and meta-analysis to elucidate other risk factors of OAG. Chapter 4 
describes the risk factors associated with visual field progression in OAG by comparing 
different statistical approaches in the Groningen Longitudinal Glaucoma Study (GLGS), a 
prospective cohort study in a clinical setting. Chapter 5 presents a systematic review and 
meta-analysis to examine the association between myopia and OAG. Chapter 6 reviews 
the current state of knowledge of the effect of systemic medications on OAG. 11 
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ABSTRACT 
 
Background: Open-angle glaucoma (OAG) is a progressive neurodegenerative disease 
that may lead to blindness. An elevated intraocular pressure (IOP) is its major risk factor. 
OAG treatment is currently exclusively directed towards the lowering of the IOP. IOP 
lowering does not prevent disease progression in all patients and thus other treatment 
modalities are needed. Earlier studies reported cholesterol-lowering drugs to have 
neuroprotective properties. The aim of this study was to determine the associations 
between the use of cholesterol-lowering drugs and incident OAG. 
 
Methodology/Principal Findings: Participants in a prospective population-based 
cohort study underwent ophthalmic examinations, including IOP measurements and 
perimetry, at baseline and follow-up. The use of statins and non-statin cholesterol-
lowering drugs (NSCLDS) was monitored continuously during the study. Associations 
between the use of cholesterol-lowering drugs and incident OAG and IOP at follow-up 
were analyzed with Cox regression and multiple linear regression respectively. During a 
mean follow-up of 9.8 years, 108 of 3939 eligible participants (2.7%) developed OAG. 
The hazard ratio for statin use was 0.54 (95% confidence interval 0.31-0.96; P=0.034) 
and for NSCLDS 2.07 (0.81-5.33; P=0.13). The effect of statins was more pronounced 
with prolonged use (hazard ratio 0.89 [0.41-1.94; P=0.77] for use two years or less; 
0.46 [0.23-0.94; P=0.033] for use more than two years; P-value for trend 0.10). The 
analyzes were adjusted for age and gender, baseline IOP and IOP-lowering treatment, 
the family history of glaucoma, and myopia. There was no effect of statins on the IOP. 
 
Conclusions/Significance: Long-term use of statins appears to be associated with a 
reduced risk of OAG. The observed effect was independent of the IOP. These findings are 
in line with the idea that statins have neuroprotective properties and may open a way to 
a new OAG treatment modality. 15 
 
INTRODUCTION 
 
Open-angle glaucoma (OAG) is a progressive neurodegenerative disease that leads to 
glaucomatous optic neuropathy and eventually, through glaucomatous visual field loss, to 
loss of sight. Together with age-related maculopathy it is the most common cause of 
irreversible blindness. An elevated intraocular pressure (IOP) is the major risk factor of 
OAG, and OAG treatment is currently exclusively directed towards the lowering of the 
IOP. However, OAG progression often continues despite an apparently sufficient reduction 
of the IOP. For that reason, the search for other OAG treatment modalities is a very 
active field of research. 
 
Statins are selective inhibitors of 3-hydroxyl-3-methylglutaryl coenzyme A reductase 
(HMG-CoA) [1]. Currently, they are the most important lipid lowering medications for the 
treatment of hypercholesterolemia [2-4]. Previous studies have reported beneficial 
effects of statins on a variety of eye diseases, including age-related maculopathy, 
cataract and diabetic retinopathy [5-11]. Several observational studies addressed the 
effects of statins on OAG. Some reported a protective effect [12-14] whereas others did 
not [15,16]. Studies including animal models as well as clinical trials have reported 
neuroprotective properties of statins [17-22]. Since OAG is characterized by the loss of 
neuronal cells, the use of statins, and possibly non-statin cholesterol-lowering drugs 
(NSCLDs) as well, might modify the risk of OAG through neuroprotection. With the 
current recommendations of lower primary prevention thresholds [23,24], the use of 
statins and NSCLDs has increased markedly over the years [25]. For these reasons, it is 
expedient to clarify the associations between these drugs and OAG. 
 
The aim of the present study was to determine the associations between the use of 
cholesterol-lowering drugs and incident OAG in a large prospective population-based 
cohort study. 16 
 
METHODS 
 
Ethics statement 
 
All measurements were conducted after the Medical Ethics Committee of the Erasmus 
University Rotterdam had approved the study protocol and all participants had given 
written informed consent in accordance with the declaration of Helsinki. 
 
Study population 
 
The present study was performed as part of the Rotterdam Study, a prospective 
population-based cohort study investigating age-related disorders. The study population 
consisted of 7983 individual’s aged 55 years and older living in the Ommoord district of 
Rotterdam, the Netherlands [26]. For this study, data from 3939 participants who did not 
have OAG (see below) at baseline and who completed at least one follow-up examination 
were used. The baseline examination took place from 1991 to 1993; follow-up 
examinations were performed from 1997 to 1999 and from 2002 to 2006. 
 
Ophthalmic assessment 
 
Participants underwent similar eye examinations at baseline and at the two follow-up 
rounds [27]. These examinations included refraction, measurement of the best-corrected 
visual acuity, Goldman applanation tonometry (Haag-Streit AG, Bern, Switzerland), 
fundoscopy, fundus photography of the posterior pole, simultaneous stereoscopic fundus 
photography of the optic disc, and visual field testing. 
 
At each visit, three IOP measurements were taken on each eye and the median value of 
these three measurements was recorded [28]; the higher median of both eyes was used 17 
 
in the analysis. The visual field of each eye was screened using a 52-point supra-
threshold test that covered the central visual field with a radius of 24° (Humphrey Field 
Analyzer [HFA]; Carl Zeiss, Oberkochen, Germany) [27,29]. Visual field loss was defined 
as non-response to a light stimulus of 6 dB above a threshold-related estimate of the hill 
of vision in at least three contiguous test points, or four including the blind spot. In 
participants with reproducible abnormalities on supra-threshold testing, Goldmann 
perimetry (Haag-Streit AG, Bern, Switzerland; baseline and first follow-up) or full-
threshold HFA 24-2 testing (second follow-up) was performed on both eyes. Visual field 
loss was considered to be glaucomatous visual field loss only if reproducible and after 
excluding all other possible causes [29,30]. 
 
Incident open-angle glaucoma 
 
We defined incident OAG as no glaucomatous visual field loss in both eyes at baseline 
and glaucomatous visual field loss in at least one eye at follow-up [30]. All identified 
cases were examined by an experienced ophthalmologist (PTVMdJ and RCWW) who 
performed gonioscopy and a dilated ophthalmic exam. Cases with a history or signs of 
angle closure or secondary glaucoma were excluded. 
 
Medication data 
 
Data on cholesterol-lowering drugs prescriptions for all participants were obtained from 
seven fully automated pharmacies using a centralized computer network in the study 
district, from January 1, 1991, onward. This included the product name, Anatomical 
Therapeutic Chemical (ATC) code, duration of use, and the date of first prescription. 
Cholesterol-lowering drugs were classified as statins (C10AA; simvastatin, pravastatin, 
fluvastatin, atorvastatin, cerivastatin, rosuvastatin) or NSCLDs (C10AB, C10AC, C10AD, 
C10A; fibrates, bile acid-binding resins or nicotinic acid and derivatives). 18 
 
The use of cholesterol-lowering drugs was rec o r d e d  a s  t h e  n u m b e r  o f  d a y s  w i t h  u s e  
during follow-up. Usage before baseline was not taken into account. 
 
Other covariates 
 
Other covariates included age, gender, smoking, diabetes mellitus, cardiovascular 
diseases, the use of antihypertensive drugs, body mass index, total cholesterol, IOP, IOP-
lowering treatment, and family history of glaucoma. All these covariates were measured 
at baseline. Smoking status was self reported and categorized as ever or never smoker. 
Data on diabetes mellitus and cardiovascular disorders such as angina pectoris, atrial 
fibrillation, myocardial infarction, heart failure, hypertension, and stroke were obtained 
from the participants through interviews, electrocardiogram readings, and non-fasting 
and fasting serum blood glucose levels. Diabetes was defined as the use of antidiabetic 
medication or by a non-fasting or post-load plasma glucose level above 200 mg/dl (11.1 
mmol/l). Hypertension was defined as the use of antihypertensive medication for the 
indication of hypertension or as a systolic blood pressure of 140 mmHg or more, or a 
diastolic pressure of 90 mmHg or more. Body mass and height were measured at the 
research center. Total serum cholesterol was measured in non-fasting blood. IOP-lowering 
treatment was defined as the use of IOP-lowering medication or a history of glaucoma 
surgery or laser trabeculoplasty. The family history of glaucoma was determined by 
interviews and was considered positive if the participant reported a history of glaucoma 
in parents, siblings or offspring. Myopia was defined as a spherical equivalent refractive 
error of -4 D and more myopia [30]. Eyes with a cataract extraction before baseline were 
excluded from this analysis. In cases with one eye with incident OAG, the refraction of 
that eye was used. In participants without OAG or OAG in both eyes, the refraction of a 
random eye was used. 
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Statistical analysis 
 
Differences in baseline characteristics between participants with and without incident 
OAG and differences in baseline characteristics between cholesterol-lowering drug users 
and non-users were evaluated using chi-square tests for categorical variables and t-tests 
for normally distributed continuous variables. To determine the associations between the 
use of cholesterol-lowering drugs and incident OAG, the use of statins or NSCLDs was 
initially defined as any use during follow-up and the associations were initially analyzed 
with chi-square tests. Subsequently, a Cox proportional hazards model was used to 
calculate hazard ratios (HR) and corresponding 95% confidence intervals (CI) for the 
associations between the use of statins or NSCLDs and incident OAG. Follow-up duration 
was used as the time axis in the model. For participants without incident OAG, the follow-
up duration was counted from the baseline visit to the last visit with reliable perimetry. 
For incident OAG cases, the follow-up ended at the first visit in which glaucomatous 
visual field loss was detected. The cholesterol-lowering drugs, age and gender, and other 
covariates with P<0.20 in the univariate comparisons were included in the multivariate 
analysis. Subsequently, the cholesterol-lowering drugs, age and gender, and other 
covariates with P<0.05 in the initial multivariate model were included in the final model. 
The use of cholesterol-lowering drugs was entered in the model as any use during follow-
up. To allow for the evaluation of a possible dose-response relationship, we also 
performed analysis after making three nominal categories based on the duration of 
medication use, being no use, cumulative use during two years or less, and cumulative 
use during more than two years (see Discussion section). The dose-response relationship 
was evaluated with a trend test. To explore the influence of cholesterol-lowering drugs on 
the IOP, we conducted a multiple linear regression analysis with IOP at follow-up as the 
dependent variable. This analysis was adjusted for IOP-lowering treatment at follow-up 
and for the same covariates as the final Cox model except for baseline IOP and IOP-
lowering treatment at baseline. 20 
 
RESULTS 
 
During a mean follow-up of 9.8 years, 108 of 3939 eligible participants (2.7%) developed 
OAG. Table 1A depicts the baseline characteristics of the study population for participants 
with and without incident OAG. Participants with incident OAG were older, more often 
male, more often had a positive family history of glaucoma, and more often had myopia. 
They also had a higher IOP and more frequently received IOP-lowering treatment. There 
was no difference between the groups regarding total serum cholesterol levels. Table 1B 
shows the baseline characteristics for cholesterol-lowering drug users and non-users. 
Participants using cholesterol-lowering drugs were younger, smoked less frequently and 
more often had diabetes mellitus, a myocardial infarction or hypertension. They also used 
more often antihypertensive drugs and had a higher total serum cholesterol level and a 
slightly higher IOP. 
 
Table 2 presents the results of the univariable analyses for the use of statins and NSCLDs 
at any time during follow-up. These univariable comparisons revealed no significant 
differences between participants with and without incident OAG. Amongst the 811 
participants using statins at any time during follow-up, the median duration of use was 
1424 days, with a range from 8 to 4114 days; amongst the 113 participants using 
NSCLDs, the median duration of use was 298 days, with a range from 7 to 3544 days. 
 
Table 3 presents the final multivariate model, adjusting for age and gender, baseline IOP 
and IOP-lowering treatment, the family history of glaucoma, and myopia. Participants 
using statins had a significant risk reduction (HR 0.54; 95% CI 0.31 to 0.96; P=0.034). 
The use of NSCLDs was not significantly associated with incident OAG (HR 2.07; 95% CI 
0.81 to 5.33; P=0.13). There was a trend towards a reduced risk of incident OAG with 
prolonged statin use.The HR was 0.89 (95% CI 0.41 to 1.94, P=0.77) for use during two 
 21 
 
years or less and 0.46 (95% CI 0.23 to 0.94, P=0.033) for use during more than two 
years. The overall P-value for trend was 0.10. 
 
The protective effect of statins could be either caused by an IOP-lowering effect of statins 
or by a direct protective effect of statins on the neural tissue. To differentiate between 
these two possibilities, we conducted a multiple linear regression analysis with IOP at 
follow-up as the dependent variable. Table 4 shows the results. As can be seen in this 
table, there was no significant IOP-lowering effect of statins. 
 
 
DISCUSSION 
 
In this large prospective population-based study, the use of statins was associated with a 
reduced risk of OAG. This effect was independent of the IOP. The risk reduction tended to 
increase with the duration of cumulative use, which supports the observed association, 
but this trend did not reach statistical significance. The use of NSCLDs was not associated 
with the development of OAG. 
 
The association between the use of statins and OAG we found is consistent with the 
results of McGwin et al. (odds ratio 0.60; 95% CI 0.39 to 0.92) [12]. They performed a 
nested case-control study in a clinical administrative database. In contrast, Owen et al. 
found no evidence for a protective effect of statins (odds ratio 0.97; 95% CI 0.88 to 
1.06) [15]. They employed a case-control study design in a primary care database. 
Similarly, Iskedjidan et al. did not find a significant association between the use of statins 
and OAG [16]. They performed a retrospective population-based evaluation in an 
administrative prescription claims database. The designs of the latter two studies might 
have complicated the classification of OAG, and the resulting misclassification might have 
biased the effect estimate. The trend of the effect seen in our study is consistent with 22 
 
previously published studies. McGwin et al. reported a significant reduction in the risk of 
OAG in patients using statins for more than 23 months [12]. De Castro et al. reported 
that the use of statins was associated with a slower progression of glaucomatous optic 
nerve atrophy [14]. In their clinical retrospective cohort study, patients using statins for 
two years showed less optic nerve head changes than patients not using statins. 
Nagaoka, et al studied the effect of statins on the retinal circulation and the IOP [31]. 
They found an IOP decrease after the administration of statins. At first sight, this seems 
to corroborate with our findings. However, our data suggested the protective effect of 
statins to be IOP independent. A possible explanation for this discrepancy might be that 
they studied the effects of statins up to one week after the initial administration whereas 
we found the most pronounced effect in those OAG cases that used statins for more than 
two years. Leung et al. reported that the use of simvastatin was associated with visual 
field stabilization in patients with normal tension glaucoma (relative risk 0.36; 95% CI 
0.14 to 0.91; P=0.030) [13]. In their prospective cohort study, 256 patients with normal 
tension glaucoma of whom thirty-one were taking simvastatin and 225 were not taking 
simvastatin were followed-up for 36 months. 
 
The use of NSCLDs was not associated with incident OAG in our study. This result 
contradicts the result of the study by McGwin et al. who found a protective effect among 
those who used NSCLDs (odds ratio 0.59; 95% CI 0.37 to 0.97) [12]. This discrepancy 
might be attributed to the low number of users of NSCLDS in our study, as depicted by 
the wide CIs. 
 
Strengths of our study include its prospective design, the large number of participants, 
the long follow-up period and the population-based setting, which minimizes selection 
bias. An inextricable limitation of the population-based design is the limited number of 
OAG cases – due to the low prevalence of OAG - and the limited number of participants 
using NSCLDs. Information bias was prevented by prospectively collected and completely 23 
 
automated pharmacy records of all prescriptions. Although this approach guarantees 
accurate prescription data, it cannot be guaranteed that all participants actually took 
their medication. Such exposure misclassification is usually similar in cases and controls 
and leads to conservative risk estimates. Hence, it may have contributed to the lack of 
effect of NSCLDs, but not to the protective effect of statins. 
 
Several other factors have been reported to be a risk factor for the incidence of OAG, 
including myopia [32], pseudoexfoliation [33], central corneal thickness [34], and age 
[30]. Of these factors, only pseudoexfoliation and age may be associated with statin use 
and may thus be confounding factors in our analysis [35-37]. Pseudoexfoliation is 
relatively rare in the Netherlands and in our study population (which might or might not 
be due to underreporting) – hampering a meaningful adjustment for pseudoexfoliation in 
our analysis. However, the absence of adjustment should have resulted in an increased 
risk whereas we found a protective effect. Age is associated with statin use but we 
adjusted our models for that. Age as a linear covariable – as we did – might result in 
under-adjustment, but in that case an increased risk should have been the result, not a 
protective effect. We included only participants aged 55 years and older. This is not a 
limitation for this specific study question, as both statin use at younger age is relatively 
rare and the prevalence of OAG below 55 years of age is very low (0.1-0.2%; to be 
compared to 1-2% above 55 years of age [27]. Finally, myopia appeared to occur – 
presumably by chance – slightly more frequent amongst cholesterol-lowering drug users 
compared to non-users (P=0.063; Table 1B) and was included in the final model. 
 
A possible limitation of this study is potential misclassification of exposure. However, such 
misclassification will be random because the outcome is – inextricably - gathered 
irrespective of exposure status. To appreciate this approach, it is important to realize that 
glaucoma development often takes more than a decade and cannot be detected in the 
earliest stages. Some factors slow down or accelerate the disease development, and thus 24 
 
make it less likely or more likely that the disease can be detected at a certain point in 
time (being our follow-up examination). Cumulative exposure stratified into biologically 
plausible nominal categories as we used in our analyses is the best proxy for studying the 
overall influence of the use of medication on the rate of glaucoma development during 
follow-up. Details of this technique were published earlier [38]. Because the exposure 
misclassification is random, it will tend to bias the results towards the null hypothesis. 
This might mean that the significant protection we found is an underestimation of the 
true effect. 
 
Our finding of a protective effect of statins may offer potential therapeutic possibilities for 
OAG or its prevention. We showed the effect to be independent of the IOP. Hence, the 
protective effect of statins could be caused by lowering serum cholesterol or by (other) 
neuroprotective properties of statins on neuronal cells, as mentioned in the Introduction 
section [17-22]. Our incident OAG cases did not have an elevated serum cholesterol level 
at baseline (Table 1), but that observation does not exclude a beneficial effect of a 
further lowering of this level - cardiovascular trials have shown beneficial effects of 
further lowering cholesterol levels even if initially already within normal limits [39,40]. 
Studies with serum cholesterol level monitoring during follow-up should enable the 
uncovering of more details of the mechanism underlying the protective effect of statins. 
Given the current level of evidence and the fact that statins are widely available and 
thoroughly investigated drugs, a neuroprotective OAG treatment could become reality 
and a randomised clinical trial seems to be a viable next step. 
 
In conclusion, we confirmed that statins appear to have a protective effect on OAG. Due 
to our study design, we were able to add that this protective effect is IOP independent. 
Hence, statins should be further explored as a new class of medications for the treatment 
of OAG, especially for those patients in whom disease progression continues despite an 
apparently sufficient IOP reduction. 25 
 
Table 1 Baseline characteristics of participants with and without incident open-angle 
glaucoma (A) and of cholesterol-lowering drug users (either statins or NSCLDs, or both) 
and non-users (B), with univariable comparisons (mean values with standard deviation 
between brackets unless stated otherwise) 
A  Incident 
open-angle 
glaucoma 
(N=108) 
No incident 
open-angle 
glaucoma 
(N=3831) 
P-value 
Age (year)  684(7.1)  65.7(6.8)  <0.001 
Gender (%female)  49.1  58.7  0.046 
Smoking (%)  33.3  33.4  0.98 
Diabetes mellitus (%)  8.4  6.9  0.54 
Angina pectoris (%)  1.9  3.1  0.46 
Atrial fibrillation (%)  2.8  2.1  0.63 
Myocardial infarction (%)  13.2  9.7  0.23 
Heart failure (%)  0.9  1.2  0.81 
Hypertension (%)  52.9  47.1  0.49 
Blood pressure lowering drugs (%)  28.0  26.0  0.63 
Stroke (%)  2.8  1.2  0.16 
Body mass index (kg/m
2) 25.8(2.9)  26.3(3.5)  0.12 
Total cholesterol (mmol/l)  6.5(1.1)  6.7(1.2)  0.17 
IOP (mmHg)  17.3(4.7)  15.0(3.1)  <0.001 
IOP-lowering treatment (%)  15.7  2.3  <0.001 
Family history of glaucoma (%)  16.7  8.1  0.002 
Myopia 9.5  4.9  0.033 
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B 
 
CLD users 
(N=848) 
Non-users 
(N=3091) 
P-value 
Age 64.3(5.5)  66.1(7.1)  <0.001 
Gender (%female)  56.6  58.9  0.23 
Smoking (%)  27.5  35.0  <0.001 
Diabetes mellitus (%)  10.2  6.1  <0.001 
Angina pectoris (%)  3.8  2.8  0.15 
Atrial fibrillation (%)  2.4  2.1  0.57 
Myocardial infarction (%)  15.3  8.2  <0.001 
Heart failure (%)  1.2  1.2  0.97 
Hypertension (%)  58.7  47.1  <0.001 
Blood pressure lowering drugs (%)  38.3  22.6  <0.001 
Stroke (%)  1.4  1.2  0.65 
Body mass index (kg/m
2) 26.5(3.5)  26.2(3.5)  0.055 
Total cholesterol (mmol/l)  7.4(1.3)  6.5(1.1)  <0.001 
IOP (mmHg)  15.3(3.2)  15.0(3.2)  0.044 
IOP-lowering treatment (%)  2.0  2.9  0.18 
Family history of glaucoma (%)  9.7  8.0  0.13 
Myopia 6.3  4.7  0.063 
 
CLD= cholesterol-lowering drugs; NSCLDs= non-statin cholesterol-lowering drugs; 
IOP = intraocular pressure. 
 
 
Table 2 Univariable analyses of the use of cholesterol-lowering medication at any time 
during follow-up and the development of open-angle glaucoma 
 Incident  open-angle 
glaucoma (N=108) 
No incident open-angle 
glaucoma (N=3831) 
P-value 
Statins (n[%])  16(14.8)  795(20.8)  0.13 
NSCLDs (n[%])  5(4.6)  108(2.8)  0.27 
 
NSCLDs = non-statin cholesterol-lowering drugs. 27 
 
Table 3 Final multivariable model of the risk of developing open-angle glaucoma for 
cholesterol-lowering medication 
 Hazard  ratio 
95% confidence 
interval 
P-value 
Statins 0.54  0.31-0.96  0.034 
NSCLDs 2.07  0.81-5.33  0.13 
Age (per year)  1.07  1.04-1.10  <0.001 
Gender (female)  0.56  0.38-0.83  0.004 
IOP (per mmHg)  1.12  1.08-1.18  <0.001 
IOP treatment  3.39  1.82-6.32  <0.001 
Family history of glaucoma  1.85  1.08-3.15  0.024 
Myopia 2.30  1.19-4.43  0.013 
 
NSCLDs = non-statin cholesterol-lowering drugs; IOP = intraocular pressure. 
 
 
Table 4 Multiple linear regression analysis with intraocular pressure at follow-up as the 
dependent variable 
 beta 
95% confidence 
interval 
P-value 
Statins  -0.006  -0.262 - 0.249  0.96 
Age (year)  -0.011  -0.026 - 0.005  0.18 
Gender (female)  -0.269  -0.479 – -0.060  0.012 
IOP-lowering treatment at follow-up  1.761  1.340 - 2.181  <0.001 
Family history of glaucoma  0.378  0.001 - 0.755  0.050 
Myopia  0.597  0.124 - 1.069  0.013 
 
IOP = intraocular pressure. 28 
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ABSTRACT 
 
Background: Data on corticosteroid-induced open-angle glaucoma in population-based 
cohort study in the elderly are limited. 
Objective: To determine whether there is an association between corticosteroid use and 
the incidence of open-angle glaucoma in the general elderly population. 
Methods: In a prospective population-based cohort study among 3939 participants aged 
55 years and above, ophthalmic examinations including measurement of the intraocular 
pressure (IOP), assessment of the optic nerve head and perimetry were performed at 
baseline and after an average follow-up duration of 9.8 years. The use of corticosteroids 
was monitored continuously during follow-up. Corticosteroids were stratified into five 
groups: ophthalmic steroids, inhaled steroids, nasal steroids, oral steroids and steroid 
ointments. Associations between the use of corticosteroids and incident open-angle 
glaucoma were assessed using logistic regression models; associations between the use 
of corticosteroids and IOP at follow-up were analyzed with multiple linear regression. 
Results: During follow-up, 108 participants (2.8%) developed glaucomatous visual field 
loss. The odds ratio of the use of ophthalmic steroids was 1.04 (95% confidence 
interval[CI] 0.66-1.65; P=0.86), inhaled steroids 0.79 (0.42-1.48; P=0.46), nasal 
steroids 1.26 (0.74-2.13; P=0.40), oral steroids 1.03 (0.65-1.64; P=0.89), and steroid 
ointments 0.70 (0.47-1.05; P=0.086). These analyzes were adjusted for age, gender, 
high myopia and family history of glaucoma. The use of corticosteroids was not 
associated with an increased IOP at follow-up. 
Conclusions: The use of any class of steroids was not associated with the incidence of 
open-angle glaucoma in this population of elderly. 
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INTRODUCTION 
 
The usage of corticosteroids for inflammatory disease dates back to the 1950’s.
1 
Currently, corticosteroids are applied successfully in many fields of medicine, including 
ophthalmology, and belong to the most frequently prescribed drugs.
2 However , they can 
produce a plethora of adverse ocular effects such as corticosteroid-induced glaucoma
3-8 
and cataract.
9-11 
 
Individuals who develop an increase in intraocular pressure (IOP) after steroid therapy 
are referred to as steroid responders.
12-14 In the literature, several risk factors have been 
identified for steroid responders. They include the presence of primary open-angle 
glaucoma (OAG)
15 or its family history,
16-18 age,
19-21 diabetes mellitus,
22 high myopia,
23 
and rheumatoid arthritis.
24 Glaucoma may develop if the IOP elevation is of sufficient 
magnitude and duration. In that case, a progressive degeneration of the optic nerve and 
a corresponding decline of the visual field may ensue: steroid-induced glaucoma.
25-27 
 
The ocular hypertensive response in steroid–induced glaucoma has been shown to occur 
with ophthalmic steroids,
28-30 inhaled steroids,
31-33 nasal steroids,
31,34 oral steroids,
35-37 
and steroid ointments.
38-41 Most of these studies are case reports or small case series; 
two studies were performed in health-insurance-plan databases.
31,37 In population-based 
epidemiology, steroid-induced glaucoma has only been addressed by the Blue Mountains 
eye study.
33 They did not find any harmful effect for ophthalmic or oral steroids; for 
inhaled steroids, an effect was seen in a subgroup of patients with a positive family 
history of glaucoma.
33 Hence, it is largely unknown if the adverse effects of steroids are 
limited to a few susceptible individuals or contribute to the burden of OAG in the 
population. The aim of this study was to explore the associations between steroid use 
and incident OAG in a population-based setting. 
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METHODS 
 
Study population 
 
The present study was performed as part of the Rotterdam Study, a prospective 
population-based cohort study of age-related disorders. The study population consisted 
of 7983 individuals aged 55 years and older living in a district of Rotterdam, the 
Netherlands.
42 For this study, data from 3939 participants who did not have glaucoma at 
baseline and who completed at least one follow-up examination were used. The baseline 
examination took place from 1991 to 1993; follow-up examinations were performed from 
1997 to 1999 and from 2002 to 2006. All measurements were conducted after the 
Medical Ethics Committee of the Erasmus University Rotterdam had approved the study 
protocol and all participants had provided written informed consent in accordance with 
the declaration of Helsinki. 
 
Ophthalmic assessment 
 
Participants underwent similar eye examinations at baseline and at the two follow-up 
rounds. These examinations included refraction, measurement of the best corrected 
visual acuity, Goldmann applanation tonometry (Haag-Streit AG, Bern, Switzerland), 
fundoscopy, fundus photography of the posterior pole, simultaneous stereoscopic fundus 
photography of the optic disc, and visual field testing. 
 
At each visit, three intraocular pressure (IOP) measurements were taken on each eye 
and the median value of these three measurements was recorded.
43 In the analyzes we 
used the highest median of the baseline IOP measurements of both eyes. The visual field 
of each eye was screened using a 52-point supra-threshold test that covered the central 
visual field with a radius of 24° (Humphrey Field Analyzer [HFA]; Carl Zeiss, Oberkochen, 35 
 
Germany).
44,45 Visual field loss was defined as non-response to a light stimulus of 6 dB 
above a threshold-related estimate of the hill of vision in at least three contiguous test 
points, or four including the blind spot. In participants with reproducible abnormalities on 
supra-threshold testing, Goldmann perimetry (Haag-Streit AG, Bern, Switzerland; 
baseline and first follow-up) or full-threshold HFA 24-2 testing (second follow-up) was 
performed on both eyes. Visual field loss was considered to be glaucomatous visual field 
loss only if reproducible and after excluding all other possible causes.
44,46 
 
Incident open-angle glaucoma 
 
We defined an incident OAG case as a participant with no glaucomatous visual field loss 
in both eyes at baseline and glaucomatous visual field loss in at least one eye at follow-
up.
46 Cases with a history or signs of angle closure (gonioscopy was performed in all 
identified cases) or secondary glaucoma (except for steroid-induced glaucoma) were 
excluded. 
 
Medication data 
 
Data on corticosteroid prescriptions for all participants were obtained from seven fully 
automated pharmacies using a centralized computer network in the Ommoord district of 
Rotterdam, the Netherlands, from January 1, 1991, onward. This included the product 
name, Anatomical Therapeutic Chemical (ATC) code, number of prescriptions, and the 
date of first prescription. Corticosteroids were classified as ophthalmic steroids (S01BA, 
S01CA), inhaled steroids (R03BA), nasal steroids (R01AD), oral steroids (ATC codes 
H02AB, H02BX), and steroid ointments (D07AA, D07AB, D07AC, D07AD). The number of 
prescriptions during follow-up was used as a proxy for cumulative dose. Usage before 
baseline was not taken into account. 
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Other covariables 
 
Other covariables included age, gender, diabetes mellitus, rheumatoid arthritis, IOP, IOP-
lowering treatment, family history of glaucoma, and myopia. All covariables were 
measured at baseline. Information on the presence of diabetes mellitus was elicited from 
the participants through interviews and blood samples. Diabetes was defined as the use 
of antidiabetic medication or by a non-fasting or post-load plasma glucose level above 
200 mg/dL (11.1 mmol/L). The presence of rheumatoid arthritis was assessed using The 
Stanford Health Assessment Questionnaire based on the International Classification of 
Impairments, Disabilities and Handicaps guidelines.
47 IOP-lowering treatment was 
defined as the use of IOP-lowering medication or a history of glaucoma surgery or laser 
trabeculoplasty. The family history of glaucoma was determined by interviews and was 
considered positive if the participant reported a history of glaucoma in parents, siblings 
or offspring. For myopia, the spherical equivalent refractive error was calculated as 
sphere+(cylinder/2) in diopters (D). Refraction was stratified into three categories: -4 D 
and more myopia (high myopia), between (but not including) -4 and 0 D (low myopia), 
and 0 D and a positive refractive error. Eyes with a cataract extraction before baseline 
were excluded from this analysis. In cases with one eye with incident OAG, the refraction 
of that eye was used. In participants without OAG or OAG in both eyes, the refraction of 
a random eye was used. 
 
Statistical analyses 
 
Differences in baseline characteristics between participants with and without incident 
OAG were evaluated using chi-square tests for categorical variables and t-tests for 
normally distributed continuous variables. The use of corticosteroids was initially 
categorized as any use during follow-up and analyzed with chi-square tests. Associations 
between incident OAG and the use of corticosteroids were assessed using logistic 37 
 
regression models. Effect estimates were presented as odds ratios (ORs) with 
corresponding 95% confidence intervals (CIs). In addition to the five groups of steroids, 
all factors that were associated with incident OAG in the univariate analyses at a P-value 
of 0.20 or less and age and gender were included in the multivariate models. Collinearity 
between the various groups of steroids was assessed by calculating Spearman's 
correlation coefficients. Furthermore, multicollinearity diagnostic statistics produced by 
linear regression analysis was carried out using PROC REG with options variance inflation 
factor (VIF) and tolerance (TOL).
48 Because many participants got only a few 
prescriptions during the entire follow-up period (see Results section), we evaluated dose-
response relationships by stratifying steroid use as no steroid use, use less than or equal 
to the median number of prescriptions and use more than the median number of 
prescriptions, where the median number of prescriptions was determined within the 
subgroup of steroid users. To explore direct effects of the steroids on the IOP, we 
conducted a multiple linear regression analysis with IOP at follow-up as the dependent 
variable. In this analysis, steroid use was defined as use more than the median number 
of prescriptions; the analysis was adjusted for the same covariables as the logistic 
regression models except for baseline IOP and IOP-lowering treatment at baseline. All 
analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC). A P-value of 0.05 
or less was considered statistically significant. 
 
 
RESULTS 
 
During a mean follow-up of 9.8 years (range 5.0-13.9 years), 108 participants (2.7%) 
developed OAG. Table 1 depicts the baseline characteristics of the study population. 
Participants with incident OAG were older, more often male, had a higher IOP at baseline, 
more frequently received IOP-lowering treatment, and more often had high myopia or a 
positive family history of glaucoma. 38 
 
Table 2 presents the results of the univariable analyses for the use of steroids at any time 
during follow-up, for all five groups of steroids. There were no significant differences 
between participants with and without incident OAG. The median (95% central range) of 
the number of prescriptions per participant as determined within the subgroup of steroid 
users was 2 (1-17) for ophthalmic steroids, 7 (1-55) for inhaled steroids, 2 (1-31) for 
nasal steroids, 2 (1-31) for oral steroids and 3 (1-37) for steroid ointments. 
 
In the multivariable logistic regression analysis for all corticosteroid classes in our study 
population, none of the classes of steroids showed a significant association with incident 
OAG. This analysis was adjusted for age, gender, baseline IOP, IOP treatment, positive 
family history of glaucoma and high myopia. Formally speaking, baseline IOP and IOP-
lowering treatment are not confounding factors in the association between steroid use 
and OAG. Moreover, since steroid use already at or before baseline might be more likely 
in those participants who used steroids during follow-up, these two variables might even 
be in the causal pathway. Table 3 shows the results of the multivariable logistic 
regression analysis after removing IOP and IOP-lowering treatment from the model. The 
risk of developing OAG remained insignificant for all classes of steroids. 
 
We repeated the analysis as presented in Table 3 after recoding the use for all classes of 
steroids in no use, use smaller than or equal to the median number of prescriptions and 
used more than the median number of prescriptions. Table 4 presents the results. The 
risk of developing OAG was not significant for any of the steroid classes. 
 
Family history, rheumatoid arthritis, high myopia and diabetes have been reported to be 
risk factors for steroid responders (see Introduction). In our study, only family history 
(P=0.002) and high myopia (0.033) showed a significant univariable association with 
OAG (Table 1). Interaction analyses with each class of steroid showed no significant 
effects for either the family history or high myopia. 39 
 
In order to rule out the possibility of collinearity, we computed the correlation coefficients 
between the various steroid classes. These coefficients were consistently less than 0.5. 
Furthermore, we calculated the ‘variance inflation factor’ (VIF) for collinearity of each 
independent variable. None of the VIFs was larger than 2.5. This indicates that the 
steroid classes may be analysed simultaneously in a single multivariable model. 
 
Table 5 shows the results of the multiple linear regression analysis with IOP at follow-up 
as the dependent variable. As can be seen in this table, there was no significant IOP-
lowering effect for any of the steroid classes. 
 
 
DISCUSSION 
 
In the elderly, the use of corticosteroids - in whatever dosage form - appears not to be 
associated with an increased risk of incident OAG at the population level. 
 
The lack of association between the use of ophthalmic steroids and OAG in our study is 
consistent with the results of the population-based Blue Mountains eye study.
33 In 
contrast, a positive association between the use of topical ophthalmic steroids and OAG 
(OR 1.72; 95% CI 1.55-1.92) was reported in a case-control study performed in a 
health-insurance-plan database.
37 The study population of that study consisted of 9793 
glaucoma cases and 38325 controls, with a mean age of 74.9 and 74.7 years for cases 
and controls respectively. The small number of users amongst the cases in our study 
might have hampered the finding of a significant association between ophthalmic steroid 
use and OAG. This is illustrated by the fact that our 95% CI for ophthalmic steroids 
(0.66-1.65; Table 3) overlapped with that of Garbe et al. (1.55-1.92). However, another 
explanation of the discrepancy between the results of our study and that of Garbe et al. 
might be a selection bias in their case-control design. 40 
 
Individuals on ophthalmic steroid therapy are more likely to visit an ophthalmologist and 
are therefore more likely to be diagnosed with ocular hypertension or OAG. Confounding 
by indication may also play a role - ophthalmic steroids may be prescribed as part of 
glaucoma treatment (laser or surgery). The cross-sectional design of Garbe et al. might 
be more sensitive to this type of bias than our longitudinal design. 
 
The lack of association between inhaled and nasal steroids and OAG we found seem to 
agree with another study by Garbe et al.
31 In that case-control study, the use of inhaled 
and nasal steroids was not associated with an increased risk of ocular hypertension or 
glaucoma. However, they found an association in a subgroup of subjects with a prolonged 
administration of high doses of inhaled steroids. The small number of incident OAG cases 
with inhaled steroid use in our study limited the value of subgroup analysis, but our 95% 
CI for inhaled steroids for the subgroup with more than the median number of 
prescriptions (0.28-1.98; Table 4) appeared to overlap with that of Garbe et al. (1.01-
2.06). In agreement with our findings, the Blue Mountains eye study did not find an 
association between inhaled steroid use and OAG. However, they found a positive 
association between inhaled steroids and elevated IOP or OAG in a subgroup of subjects 
with a positive family history of glaucoma.
33 In our data, the interaction between the 
family history of glaucoma and the use of inhaled steroids was not significant. As 
explained by the authors, a possible explanation for this finding by the Blue Mountain eye 
study might be due to the fact that they collected limited information on steroid use. The 
resulting missing data for steroid use might have induced a bias if the participants with 
and without missing data on corticosteroid use had different characteristics (differential 
misclassification). 
 
The use of oral steroids was also not associated with OAG in our study. The Blue 
Mountains eye study reported, in agreement with our finding, no significant association 
between the use of oral steroids and glaucoma in a population-based cross-sectional 41 
 
study.
33 The association between oral steroids and OAG was also investigated in the 
abovementioned health-insurance-plan database case-control study.
37 In that study, 
current use of oral steroids was shown to increase the risk of ocular hypertension or OAG 
(OR 1.41; 95% CI 1.22-1.63). As mentioned above, the discrepancy between this finding 
and our results might be either attributed to a selection bias in their case-control design 
(false-positive association) or to the limited number of incident OAG cases using oral 
steroids in our data (false-negative association). Here, our 95% CI (0.65-1.64) also 
overlapped with that of Garbe et al. (1.22-1.63). 
 
Finally, we found no significant association between the use of steroid ointments and 
OAG. Thus far, this seems not to have been investigated in any other large study, but 
several case reports have raised concerns about a possible association between steroid 
ointments use and glaucoma.
6-8,38-41,49-52,57-59 Steroid ointments may reach the eye via 
systemic absorption through the skin, they may be directly absorbed into the eye if 
intentionally used at the lid margins, or contamination of the eye may occur through the 
hand after topical application on other locations. 
 
One possible explanation for the absence of any significant effect in our study could be 
the simultaneous assessment of several groups of steroids in a single multivariable 
model. Although the collinearity analysis suggested that our approach was justified, we 
repeated our multivariable analysis as presented in Table 3, with one group of steroids at 
a time. None of the steroid types showed a significant change in OR. We also explored 
the association between any steroid use and incident OAG by combining all steroid 
groups (ophthalmic, inhaled, nasal, oral and steroid ointments) into a single variable. 
There was no significant association (OR 1.15; 95% CI 0.72-1.85; adjusted for age, 
gender, family history and myopia). It is also possible that the sensitivity to steroids is 
age dependent. Since most diseases that require a longstanding steroid treatment start 
well before the age of 55, a possible explanation for the absence of any clear effect of 42 
 
corticosteroids in our study population could be that those who are sensitive to steroids 
develop OAG before the age of 55 and are therefore not represented in our study cohort 
because we excluded individuals with glaucoma at baseline. In the literature, we found 
41 case reports together reporting on 74 cases.
3-8,28-30,32,34-36,38-41,49-72 The median age of 
these cases was 32 years, with a range from 3 weeks to 80 years. Sixty of the 74 cases 
(81%) had an age below the youngest age of 55 years of our study cohort. In the 74 
cases, the OAG was presumed to be caused by ophthalmic steroids in 38 cases,
3-5,8,28-
30,53-55,60-62,66-69,71,72 by inhaled steroids in one case,
32 by nasal steroids in two cases,
34 by 
oral steroids in eight cases,
35,36,53,56,63-65 and by steroid ointments in 31 cases.
6-8,38-41,49-
52,57-59 Armaly reported that steroid-induced effects were greater in older eyes compared 
with younger eyes and in glaucomatous eyes compared with non-glaucomatous 
eyes.
21,54,55 Lam et al. reported that the ocular hypertensive response to topical steroids 
is dose and age dependent with a peak in children aged six years or younger compared 
with children older than six.
73 Yamashita et al. reported on the use of systemic 
corticosteroids in five children with acute lymphoblastic leukemia who were followed up 
to age six. In these children, the steroid use was associated with an IOP elevation that 
was strong enough to develop glaucomatous optic neuropathy.
19 Kwok et al. performed a 
randomized control trial in 19 patients. In their study, 56% of the studied children were 
high responders to topical dexamethasone and they concluded that the ocular-
hypertensive response to topical dexamethasone in children occurs more frequently, 
more severely, and more rapidly than that reported in adults.
20 Jones and Rhee 
suggested in a review article that age is a risk factor which appears to occur in a bimodial 
distribution peaking at an age of six years and at late adulthood.
25 Finally, in a recently 
published nested case-control study using databases from the Quebec provincial health 
insurance plan, Gonzalez et al reported that current use and continuous use of inhaled 
steroids did not result in an increased risk of glaucoma or raised intra-ocular pressure 
requiring treatment in subjects aged 66 years and older.
74 
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Obviously, the effect of age is difficult to address, since those who are classified as 
steroid responder at young age may be glaucoma patients at old age. 
 
The strength of the current study is its design, a prospective population-based cohort 
study. This design minimizes the risk of biased results. Further, the use of a fully 
automated system for prescription-only drugs ensures very accurate and complete data 
since it by-passes the need of participants correctly remembering and reporting their 
past and present medication use. Obviously, although, very accurate prescription data 
were available, it cannot be guaranteed that all participants actually took their 
medication. Moreover, especially with ointments, it is difficult to estimate the dosage 
reliably from the number of prescriptions. A limitation of the population-based design is 
the limited number of incident OAG cases and the limited numbers of users in some 
corticosteroid classes. The number of cases could be increased by including our possible 
OAG cases, being those who had reached the 97.5
th percentile of the disc-area adjusted 
cup-to-disc ratio in at least one eye at follow-up but did not have glaucomatous visual 
field loss.
46 This might improve the statistical power but might also induce random 
misclassification of the outcome measure. Adding these cases did not change any of the 
results presented in this study significantly (data not shown). Finally, we were unable to 
investigate whether the risk varies with age because our study cohort included only 
individuals aged 55 years and older (see previous paragraph). 
 
In conclusion, steroid-induced glaucoma, albeit a dangerous and potentially blinding 
entity in some groups of patients, does not contribute significantly to the glaucoma 
burden in the general elderly population. 44 
 
Table 1: Baseline characteristics of participants with and without incident open-angle 
glaucoma (mean values with standard deviation in brackets unless stated otherwise) 
 
Incident open-
angle glaucoma 
(N=108) 
No open-angle 
glaucoma 
(N=3831) 
P-value 
Age (year)  68.4(7.1)  65.7(6.8)  <0.001 
Gender (n[%] female)  53(49.1)  2248(58.7)  0.046 
Diabetes mellitus (n[%])†  9(8.4)  264(6.9)  0.54 
Rheumatoid arthritis (n[%])‡  3(2.8)  81(2.1)  0.65 
IOP (mmHg)  17.3(4.7)  15.0(3.1)  <0.001 
IOP-lowering treatment (n[%]) 17(15.7)  88(2.3)  <0.001 
Positive family history of glaucoma 
(n[%])* 
18(16.7) 311(8.1)  0.002 
Myopia (n[%])**  Low  22(21.0)  770(20.3)  0.88 
 High  10(9.5)  186(4.9)  0.033 
 
IOP = intraocular pressure; † = 30 participants had missing data on diabetes mellitus; ‡ 
= 33 participants had missing data on rheumatoid arthritis; * = 8 participants had 
missing data on their family history of glaucoma; ** = 47 participants had missing data 
on myopia due to prior cataract surgery. 45 
 
Table 2: Univariable analyses of the use of each class of corticosteroids at any time 
during follow-up and the development of incident open-angle glaucoma (number of 
participants with percentage in brackets) 
 
iOAG 
(N=108) 
No -OAG 
(N=3831) 
Odds ratio 
95% confidence 
interval 
P-value 
Ophthalmic 
steroids 
30(27.8) 848(22.1)  1.35  0.88-2.08  0.17 
Inhaled steroids  13(12.0)  559(14.6)  0.80  0.45-1.44 0.46 
Nasal steroids  18(16.7)  603(15.7)  1.07  0.64-1.79  0.79 
Oral steroids  31(28.7)  1142(29.8)  0.95  0.62-1.45 0.80 
Steroid 
ointments 
51(47.2) 2100(54.8)  0.74  0.50-1.08  0.12 
 
iOAG= incident open-angle glaucoma 46 
 
 
Table 3: Multivariable analysis of the risk of developing incident open-angle glaucoma 
for all classes of corticosteroids adjusted for age, gender, positive family history of 
glaucoma and high myopia 
 Odds  ratio 
95% Confidence 
Interval 
P-value 
Ophthalmic steroids  1.04  0.66-1.65  0.86 
Inhaled steroids  0.79  0.42-1.48  0.46 
Nasal steroids  1.26  0.74-2.13  0.40 
Oral steroids  1.03  0.65-1.64  0.89 
Steroid ointments  0.70  0.47-1.05  0.086 
Age (per year)  1.06  1.04-1.09  <0.001 
Gender (female)  0.63  0.43-0.93  0.022 
Positive family history of 
glaucoma 
2.24 1.31-3.84  0.003 
High myopia  2.22  1.13-4.38  0.021 
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Table 4: Dose-response effects: multivariable analysis of the risk of developing incident 
open-angle glaucoma for all classes of corticosteroids for use less than or equal to the 
median number of prescriptions (upper row) and use more than the median number of 
prescriptions (lower row), adjusted for age, gender, positive family history of glaucoma 
and high myopia 
 Odds  ratio 
95% Confidence 
Interval 
P-value 
Ophthalmic steroids  0.81  0.44-1.46  0.48 
 1.52  0.84-2.77  0.17 
Inhaled steroids  0.95  0.45-2.02  0.89 
 0.74  0.28-1.98  0.55 
Nasal steroids  1.27  0.66-2.44  0.47 
 1.24  0.55-2.78  0.61 
Oral steroids  1.34  0.80-2.23  0.27 
 0.68  0.32-1.45  0.31 
Steroid ointments  0.82  0.51-1.30  0.39 
 0.60  0.35-1.01  0.055 
Age (per year)  1.07  1.04-1.09  <0.001 
Gender (female)  0.62  0.42-0.92  0.017 
Positive family history of 
glaucoma 
2.24 1.31-3.85  0.003 
High myopia  2.24  1.13-4.42  0.020 
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Table 5: Multiple linear regression analysis with intraocular pressure at follow-up as the 
dependent variable 
 beta  95% Confidence 
Interval 
P-value 
Ophthalmic steroid  0.490  -0.336 to 0.433 0.80 
Inhaled steroids  -0.348  -0.792 to 0.096 0.13 
Nasal steroids  0.159  -0.268 to 0.586 0.47 
Oral steroids  -0.212  -0.539 to 0.115 0.20 
Steroid ointments  0.006  -0.234 to 0.246 0.96 
Age (per year)  -0.005  -0.020 to 0.011 0.57 
Gender (female)  -0.296  -0.508 to -0.085  0.006 
Positive family history of glaucoma  0.513  0.134 to 0.892 0.008 
High myopia  0.666  0.189 to 1.142 0.006 
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ABSTRACT 
 
Purpose: To determine the associations between the use of antithrombotic drugs and 
incident open-angle glaucoma (OAG). 
Methods: Ophthalmic examinations including measurements of the intraocular pressure 
(IOP) and perimetry were performed at baseline and follow-up in 3939 participants of the 
prospective population-based Rotterdam Study who did not have OAG at baseline. The 
use of antithrombotic drugs was monitored continuously during follow-up. 
Antithrombotics were stratified into anticoagulants and platelet aggregation inhibitors. 
Associations between incident OAG and the use of antithrombotics were assessed using 
Cox regression models; associations between antithrombotics and IOP at follow-up were 
analyzed with multiple linear regression. 
Results: During a mean follow-up of 9.8 years, 108 participants (2.7%) developed OAG. 
The hazard ratio for anticoagulant use was 0.90 (95% confidence interval 0.55 to 1.48; 
P=0.69) and for platelet aggregation inhibitors 0.80 (0.53 to 1.21; P=0.28). There was 
no trend towards a reduced or increased risk of incident OAG with prolonged 
anticoagulant use (P-value for trend 0.84) or platelet aggregation inhibitor use (0.59). 
The analyses were adjusted for age, gender, baseline IOP and IOP-lowering treatment, 
family history of glaucoma and myopia. There was a significant IOP-lowering effect of 
anticoagulants (-0.31 mmHg; 95% confidence interval -0.58 to -0.04 mmHg; P=0.025) 
but not of platelet aggregation inhibitors (P=0.06). The IOP-lowering effect of 
anticoagulants disappeared after additional adjustment for the use of systemic beta-
blockers. 
Conclusions: Use of anticoagulants or platelet aggregation inhibitors appears not to be 
associated with incident OAG. 57 
 
INTRODUCTION 
 
Open-angle glaucoma (OAG) is an insidious disease characterized by irreversible loss of 
retinal ganglion cells and cupping of the optic disc, ultimately resulting in loss of sight. 
The prevalence of OAG in the 40+ population is approximately 2%.
1 An elevated IOP is 
an important risk factor for OAG and the therapeutic management of OAG is currently 
targeted towards the lowering of IOP. However, OAG progression often continues despite 
an apparently sufficient reduction of the IOP. As this IOP-independent progression is at 
best partially understood, more research is needed to elucidate the pathogenesis of OAG, 
which may result in the development of other therapeutic strategies. 
 
Impaired blood flow has been postulated to be involved in the pathogenesis of OAG.
2,3 
Treatment with antithrombotic drugs such as anticoagulants and platelet aggregation 
inhibitors (PAIs) is a frequently used prophylaxis against impaired blood flow.
4 Moreover, 
PAIs have been suggested to have neuroprotective properties.
5 Some clinicians already 
prescribe PAIs based on a “it does not hurt to try” principle. However, two recent trials in 
Alzheimer's disease (like OAG a neurodegenerative disease) showed no effect of PAIs 
(aspirin) on cognitive functioning whereas it increased the risk of serious bleeds.
6,7 For all 
these reasons, it seems logical to study the potential role of these drugs in the 
management of OAG, as suggested earlier.
8 Thus far, one study addressed the effect of 
PAIs(acetylsalicyclic acid; ASA) on IOP
9  and two studies the effect of ASA on the 
progression of OAG.
10,11 As these studies gave equivocal results (see Discussion), another 
look at this issue seemed warranted. Moreover, we did not find any study addressing the 
effects of anticoagulants or of PAIs other than ASA on OAG. 
 
The aim of this study was to determine the associations between the use of anti- 
coagulants or PAIs and the development of OAG in a prospective population-based cohort 
study. 58 
 
METHODS 
 
Study population 
 
The present study was performed as part of the Rotterdam Study, a prospective 
population-based cohort study investigating age-related disorders. The study population 
consisted of 7983 individuals aged 55 years and older living in the Ommoord district of 
Rotterdam, the Netherlands.
12 For this study, data from a subset of 3939 participants 
who did not have OAG (see below) at baseline and who completed at least one follow-up 
examination were used. The baseline examination took place from 1991 to 1993; follow-
up examinations were performed from 1997 to 1999 and from 2002 to 2006. All 
measurements were conducted after the Medical Ethics Committee of the Erasmus 
University Rotterdam had approved the study protocol and all participants had given 
written informed consent in accordance with the declaration of Helsinki. 
 
Ophthalmic assessment 
 
Participants underwent similar eye examinations at baseline and at the two follow-up 
rounds. These examinations included refraction, measurement of the best-corrected 
visual acuity, Goldmann applanation tonometry (Haag-Streit AG, Bern, Switzerland), 
fundoscopy, fundus photography of the posterior pole, imaging of the optic disc, and 
visual field testing. 
 
At each visit, three IOP measurements were taken on each eye and the median value of 
these three measurements was recorded 
13 ; the higher median of both eyes was used in 
the analysis. The visual field of each eye was screened using a 52-point supra-threshold 
test that covered the central visual field with a radius of 24° (Humphrey Field Analyzer 
[HFA]; Carl Zeiss, Oberkochen, Germany).
14,15 59 
 
Visual field loss was defined as non-response to a light stimulus of 6 dB above a 
threshold-related estimate of the hill of vision in at least three contiguous test points, or 
four including the blind spot. In participants with reproducible abnormalities on supra-
threshold testing, Goldmann perimetry (Haag-Streit AG, Bern, Switzerland; baseline and 
first follow-up) or full-threshold HFA 24-2 testing (second follow-up) was performed on 
both eyes. Visual field loss was considered to be glaucomatous visual field loss only if 
reproducible and after excluding all other possible causes.
14,16 
 
Incident open-angle glaucoma 
 
We defined incident OAG as no glaucomatous visual field loss in both eyes at baseline 
and glaucomatous visual field loss in at least one eye at follow-up.
 16 All identified cases 
were examined by an experienced ophthalmologist (PTVMdJ and RCWW) who performed 
gonioscopy and a dilated ophthalmic exam. Cases with a history or signs of angle closure 
or secondary glaucoma were excluded. 
 
Medication data 
 
Data on antithrombotic drugs prescriptions for all participants were obtained from seven 
pharmacies using a centralized computer network in the Ommoord district of Rotterdam, 
the Netherlands, from January 1, 1991, onward. This included the product name, 
Anatomical Therapeutic Chemical (ATC) code, duration of use, and the date of first 
prescription. Antithrombotic drugs were classified based on ATC system according to 
pharmacological subgroup into anticoagulants (B01AA; coumarin derivatives) and PAIs 
(B01AC; abciximab, ASA, carbasalate calcium, clopidogrel, dipyridamole, eptifibatide, 
prasugrel, tirofiban). The use of antithrombotics was recorded as the number of days 
with use during follow-up. Usage before baseline was not taken into account. 
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Other covariables 
 
Other covariables included age, gender, smoking, diabetes mellitus, cardiovascular 
diseases, the use of antihypertensive drugs, the use of statins, body mass index, total 
cholesterol, IOP, IOP-lowering treatment, and family history of glaucoma. All these 
covariables were measured at baseline. Smoking status was self-reported and 
categorized as ever or never smoker. Data on diabetes mellitus and cardiovascular 
disorders such as angina pectoris, atrial fibrillation, myocardial infarction, heart failure, 
hypertension and stroke were obtained from the participants through interviews, 
electrocardiogram readings, and non-fasting and fasting serum blood glucose levels. 
Diabetes was defined as the use of antidiabetic medication or by a non-fasting or post-
load plasma glucose level above 200 mg/dl (11.1 mmol/l). Hypertension was defined as 
the use of antihypertensive medication for the indication of hypertension or as a systolic 
blood pressure of 140 mmHg or more, or a diastolic pressure of 90 mmHg or more. The 
use of antihypertensive medication and statins was determined using the pharmacy 
computer system as described above. Body mass and height were measured at the 
research center. Total serum cholesterol was measured in non-fasting blood. IOP-lowering 
treatment was defined as the use of IOP-lowering medication or a history of glaucoma 
surgery or laser trabeculoplasty. The family history of glaucoma was determined by 
interviews and was considered positive if the participant reported a history of glaucoma 
in parents, siblings or offspring. Myopia was defined as a spherical equivalent refractive 
error of -4 D and more myopia. Eyes with a cataract extraction before baseline were 
excluded from this analysis. In cases with one eye with incident OAG, the refraction of 
that eye was used. In participants without OAG or OAG in both eyes, the refraction of a 
random eye was used. 
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Statistical analysis 
 
Differences in baseline characteristics between participants with and without incident 
OAG and differences in baseline characteristics between anti-thrombotic drug users and 
non-users were evaluated using chi-square tests for categorical variables and t-tests for 
normally distributed continuous variables. To determine the associations between the use 
of anti-thrombotic drugs and incident OAG, the use of anticoagulants or PAIs was initially 
defined as any use during follow-up and the associations were initially analyzed with chi-
square tests. Subsequently, a Cox proportional hazards model was used to calculate 
hazard ratios (HR) and corresponding 95% confidence intervals (CI) for the associations 
between the use of anticoagulants or PAIs and incident OAG. Follow-up duration was 
used as the time axis in the model. For participants without incident OAG, the follow-up 
duration was counted from the baseline visit to the last visit with reliable perimetry. For 
incident OAG cases, the follow-up ended at the first visit in which glaucomatous visual 
field loss was detected. The antithrombotic drugs, age and gender, and other covariables 
with P<0.20 in the univariate comparisons were included in the multivariate analysis. 
Subsequently, the antithrombotic drugs, age and gender, and other covariables with 
P<0.05 in the initial multivariate model were included in the final model. The use of 
antithrombotic drugs was entered in the model as any use during follow-up. To allow for 
the evaluation of a possible dose-response relationship, we also performed analysis after 
making three nominal categories based on the duration of medication use, being no use, 
cumulative use during two years or less, and cumulative use during more than two years 
(see Discussion). The dose-response relationship was evaluated with a trend test. To 
explore direct effects of the antithrombotics on the IOP, we conducted a multiple linear 
regression analysis with IOP at follow-up as the dependent variable. This analysis was 
adjusted for IOP-lowering treatment at follow-up and for the same covariates as the final 
Cox model except for baseline IOP and IOP-lowering treatment at baseline. All analyzes 
were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) and P ≤ 0.05 is significant. 62 
 
RESULTS 
 
During a mean follow-up of 9.8 years, 108 participants (2.7%) developed OAG. Table 1A 
depicts the baseline characteristics of the study population for participants with and 
without incident OAG. Participants who developed OAG were older and more often male, 
more often had a positive family history of glaucoma, and more often had myopia. They 
also had a higher IOP and more frequently received IOP-lowering treatment. Table 1B 
shows the baseline characteristics of the study population for antithrombotic drug users 
and non-users. 
 
Table 2 presents the results of the univariable analyses for the use of antithrombotic 
drugs at any time during follow-up. There was no significant difference between OAG 
cases who used either anticoagulants or PAIs and the controls. Amongst the 722 
participants using anticoagulants at any time during follow-up, the median duration of 
use was 231 days, with a range from 1 to 3823 days; amongst the 1388 participants 
using PAIs, the median duration of use was 1112 days, with a range from 7 to 4411 
days. 
 
Table 3 presents the final model, adjusting for age, gender, baseline IOP and IOP-
lowering treatment, the family history of glaucoma and myopia. Participants using 
anticoagulants and PAIs had non-significant risk reductions with HRs of 0.90 and 0.80, 
respectively. There was no trend towards a reduced or increased risk of incident OAG 
with prolonged anticoagulant use (HR 0.84 [95% CI 0.46-1.53; P=0.57] for usage during 
two years or less; HR 1.04 [95% CI 0.48-2.27; P=0.92] for usage during more than two 
years; P-value for trend 0.84) or PAI use (HR 0.78 [95% CI 0.42-1.45; P=0.44] for 
usage during two years or less; HR 0.81 [95% CI 0.51-1.31; P=0.40] for usage during 
more than two years; P-value for trend 0.59). 
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Table 4 shows the results of the multiple linear regression analysis with IOP at follow-up 
as the dependent variable. As can be seen in this table, there was a significant IOP-
lowering effect of anticoagulants but this effect was not seen in PAIs. 
 
DISCUSSION 
 
This study did not demonstrate any association between the use of either anticoagulants 
or PAIs and incident OAG. Interestingly, the use of anticoagulants seemed to be 
associated with a lower IOP. 
 
In a retrospective cohort study performed in a clinical setting, de Castro et al examined 
the effect of ASA on the optic nerve head as assessed longitudinally with confocal 
scanning laser ophthalmoscopy in 76 OAG suspects.
11 They did not find an effect of ASA 
use after a follow-up of 23 months, which is in agreement with our findings. Linden et al 
conducted a double blind, placebo controlled randomized, crossover study amongst 28 
patients with OHT or OAG to determine the short-term effect of a single dosis of 500 mg 
ASA on the IOP. There was no statistically significant difference between the placebo 
treated and the ASA treated patients.
9 This is in agreement with our observation that the 
usage of PAIs was not associated with the IOP at follow-up. Bell et al found, in a 
retrospective observational case-control study amongst 64 patients undergoing 
trabeculectomy and 74 controls, an association between ASA use and an increased 
frequency of glaucoma surgery, suggesting a harmful effect (Bell 2004).
10 The major 
limitation of their study as reiterated by the authors was that they equated the frequency 
of glaucoma surgery with the progression of glaucoma. This assumption might have 
biased the effect estimate. Although they found a significant harmful effect whereas we 
did not, the 95% CI for ASA use in their study (1.10-4.79) overlaps with our 95% CI for 
PAIs use (0.53-1.21). 
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Although we did not find a significant beneficial or harmful effect of anticoagulants or 
PAIs on the incidence of OAG, there was a significant IOP-lowering effect of 
anticoagulants. Interestingly, the anticoagulant heparin has been associated with an 
increased outflow facility in human and monkey trabecular meshwork 
17-19, providing at 
least a glimpse of a possible biological explanation for this unexpected finding. Although 
our finding may thus support a hypothesis regarding IOP regulation, the clinical 
significance is at most modest, as the R
2 was only 0.03 (that is, the percentage of the 
IOP at follow-up explained by the anticoagulant use in the regression model was 3%) and 
the effect estimate was only approximately -0.3 (that is, those using anticoagulants had - 
on average – a 0.3 mmHg lower IOP than those not using anticoagulants). The 
combination of a significant IOP-lowering effect and no effect on the incidence of OAG 
might point to a harmful IOP-independent effect of anticoagulants on OAG. However, with 
a 12% increase in OAG risk per mmHg increase in IOP (Table 3), the effect of a 0.3 
mmHg lowering of the IOP is amply within the 95% CI as reported in Table 3. Apart from 
a possible biological mechanism explaining the IOP-lowering effect of anticoagulants, 
confounding by, for example, the use of systemic beta-blockers at follow-up could be a 
possible confounding factor. If we adjusted the analysis as presented in Table 4 for beta-
blocker use at follow-up, the IOP-lowering effect of anticoagulants was no longer 
significant (effect estimate -0.031 mmHg; P=0.78). 
 
In an earlier study, we reported that the use of statins was associated with a reduced risk 
of OAG (chapter 1). Therefore, the use of statins may be regarded as a confounder in the 
present study. In the present study, we corrected – in accordance with the assumptions 
of the Cox model - for the use of statins at baseline. As the use of statins increases 
rapidly with age, we explored adjusting for statin use during follow-up as well. No 
changes were observed in the HRs of either the anticoagulants or the PAIs. 
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Strengths of our study include its prospective and population-based design, the large 
number of participants and the long follow-up period. Information bias was prevented by 
prospectively and completely automated collected pharmacy records of all prescriptions. 
Although this approach guarantees accurate prescription data, a complete overview of 
medication prescriptions does not guarantee that all participants actually took their 
medication. In this respect it is important to mention that the monitoring of the users of 
anticoagulants is well organized in the Netherlands (by means of regular blood sampling 
and the provision of personalized dosing schemes). Also, especially the PAIs that 
irreversibly block the platelet aggregation (like ASA) have a long therapeutic half-life 
(approximately 10 days; determined by the physiological turnover of platelets). This 
should make the effect of these drugs resistant against an irregular intake. Nevertheless, 
non-compliance may have resulted in a too conservative risk estimate, inhibiting the 
discovery of small harmful or protective effects. 
 
A possible limitation of this study is potential misclassification of exposure. This 
misclassification will be random because the outcome is – inextricably - gathered 
irrespective of exposure status. To appreciate this approach, it is important to realize that 
OAG development often takes more than a decade and cannot be detected in the earliest 
stages. Some factors slow down or accelerate the disease development, and thus make it 
less likely or more likely that the disease can be detected at a certain point in time (being 
our follow-up examination). Cumulative exposure stratified into biologically plausible 
nominal categories as we used in our analyses is the best proxy for studying the overall 
influence of the use of medication on the rate of glaucoma development during follow-
up.
20 Because the exposure misclassification is random, it will tend to bias the results 
towards the null hypothesis. This might have hampered the detection of small protective 
or harmful effects in our study. 
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To the best of our knowledge, this is the first study examining the effects of the use of 
anticoagulants on OAG, and the first population-based study examining the effects of 
PAIs on OAG. Given no clear protective or harmful effects, our study does not support 
prescribing or withdrawing either anticoagulants or PAIs in patients with OAG. 67 
 
Table 1 Baseline characteristics of participants with and without incident open-angle 
glaucoma (A) and of antithrombotic users (either anticoagulants or platelet aggregation 
inhibitors, or both) and non-users (B), with univariable comparisons (mean values with 
standard deviation between brackets unless stated otherwise) 
A  Incident open-
angle glaucoma 
(N=108) 
No incident open-
angle glaucoma 
(N=3831) 
P-value 
Age 68.4(7.1)  65.7(6.8)  <0.001 
Gender (%female)  49.1  58.7  0.046 
Smoking (%)  33.3  33.4  0.98 
Diabetes mellitus (%)  8.4  6.9  0.54 
Angina pectoris (%)  1.9  3.1  0.46 
Atrial fibrillation (%)  2.8  2.1  0.63 
Myocardial infarction (%)  13.2  9.7  0.23 
Heart failure (%)  0.9  1.2  0.81 
Hypertension (%)  52.9  47.1  0.49 
Stroke (%)  2.8  1.2  0.16 
Use of antihypertensive drugs (%)  28.0  26.0  0.63 
Use of statins (%)  0.9  2.1  0.39 
Body mass index (kg/m
2) 25.8(2.9)  26.3(3.5)  0.12 
Total cholesterol (mmol/l)  6.5(1.1)  6.7(1.2)  0.17 
IOP (mmHg)  17.3(4.7)  15.0(3.1)  <0.001 
IOP-lowering treatment (%)  15.7  2.3  <0.001 
Family history of glaucoma (%)  16.7  8.1  0.002 
Myopia 9.5  4.9  0.033 68 
 
 
B  Antithrombotic 
users (N=1748) 
Non-users 
(N=2191) 
P-value 
Age 67.3(6.9)  64.5(6.6)  <0.001 
Gender (%female)  55.0  61.1  <0.001 
Smoking (%)  32.6  34.1  0.31 
Diabetes mellitus (%)  9.2  5.2  <0.001 
Angina pectoris (%)  4.7  1.8  <0.001 
Atrial fibrillation (%)  3.8  0.8  <0.001 
Myocardial infarction (%)  15.1  5.5  <0.001 
Heart failure (%)  2.0  0.5  <0.001 
Hypertension (%)  57.3  43.5  <0.001 
Stroke (%)  2.3  0.5  <0.001 
Use of antihypertensive drugs (%)  35.5  18.5  <0.001 
Use of statins (%)  32.2  11.3  <0.001 
Body mass index (kg/m
2) 26.6(3.5)  26.1(3.5)  <0.001 
Total cholesterol (mmol/l)  6.7(1.2)  6.7(1.2)  0.82 
IOP (mmHg)  15.1(3.2)  15.0(3.2)  0.35 
IOP-lowering treatment (%)  2.5  2.8  0.47 
Family history of glaucoma (%)  8.0  8.6  0.50 
High myopia  5.1  5.0  0.95 
 
IOP = intraocular pressure. 69 
 
Table 2 Univariable analyses of the use of antithrombotic drugs at any time during 
follow-up and the development of open-angle glaucoma 
 iOAG 
(N=108) 
No-iOAG 
(N=3831) 
P-values 
Anticoagulants (n[%])  21(19.4)  701(18.3)  0.76 
PAIs (n[%])  40(37.0)  1348(35.2)  0.69 
 
iOAG= incident open-angle glaucoma; PAIs= platelet aggregation inhibitors 
 
 
Table 3 Final multivariable model of the risk of developing open-angle glaucoma for 
antithrombotic drugs 
 Hazard  ratio 
95% confidence 
interval 
P-value 
Anticoagulants 0.90  0.55-1.48  0.69 
Platelet aggregation inhibitors  0.80  0.53-1.21  0.28 
Age (per year)  1.08  1.05-1.11  <0.001 
Gender (female)  0.57  0.39-0.85  0.005 
IOP (per mmHg)  1.12  1.08-1.18  <0.001 
IOP treatment  3.24  1.73-6.08  0.002 
Family history of glaucoma  1.82  1.06-3.11  0.029 
Myopia 2.09  1.08-4.04  0.028 
 
IOP = intraocular pressure. 70 
 
Table 4 Multiple linear regression analysis with intraocular pressure at follow-up as the 
dependent variable 
 beta 
95% confidence 
interval 
P-value 
Anticoagulants -0.31  -0.58  to  -0.04  0.025 
Platelet aggregation inhibitors  -0.21  -0.44 to 0.008  0.06 
Age (year)  -0.006  -0.021 to 0.010  0.49 
Gender (female)  -0.30  -0.51 to -0.09  0.006 
IOP-lowering treatment at follow-up  1.76  1.34 to 2.18  <0.001 
Family history of glaucoma  0.37  -0.01 to 0.75  0.054 
Myopia  0.60  0.13 to 1.08  0.012 
 
IOP = intraocular pressure. 71 
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ABSTRACT 
 
Purpose: To identify risk factors for visual field progression in glaucoma and to compare 
different statistical approaches to this risk factor analysis. 
Patients and Methods: We included 221 eyes of 221 patients. Progression was 
analyzed using Nonparametric Progression Analysis applied to Humphrey Field Analyzer 
(HFA) data. Risk factors were analyzed using the statistical approaches from the 
Advanced Glaucoma Intervention Study (AGIS), the Early Manifest Glaucoma Trial 
(EMGT) and the Canadian Glaucoma Study (CGS). Four intraocular pressure (IOP) 
variables (baseline IOP, mean IOP during follow-up, IOP fluctuation, and pre-treatment 
IOP) and eight other risk factors were investigated. 
Results: On average 7.2 reliable fields were available after a mean follow-up of 5.4 
years; 89 eyes progressed. With the AGIS approach, age (odds ratio 1.03 per year; 95% 
confidence interval 1.00-1.06; P=0.044) predicted progression. With an additional 
stepwise selection procedure, mean IOP during follow-up (1.16 per mmHg; 1.05-1.29; 
P=0.003), baseline HFA mean deviation (MD; 2.72 for better versus worse than -6 dB; 
1.50-4.95; P=0.001) and age (1.03; 1.01-1.06; P=0.010) predicted progression. With 
the EMGT approach, baseline IOP (hazard ratio 1.07; 1.02-1.11; P=0.010), baseline 
Frequency Doubling Perimeter (FDT) MD (1.75; 1.14-2.70; P=0.013) and age (1.03; 
1.01-1.05;  P=0.006) predicted progression, and with the CGS approach, baseline IOP 
(1.07; 1.02-1.11; P=0.010), baseline FDT MD (1.75; 1.14-2.70; P=0.013) and age 
(1.03; 1.01-1.05; P=0.012). 
Conclusions: IOP, disease stage and age appeared to be robust independent risk factors 
for visual field progression in glaucoma. The IOP variable that was significant depended 
on the statistical approach applied. 75 
 
INTRODUCTION 
 
Over the past few decades, a number of studies have contributed to elucidating the risk 
factors associated with or predictive for glaucoma progression.
1-14 A good understanding 
of these risk factors is a prerequisite for estimating the risk of progression in individual 
patients. Knowledge of individual progression risks enables custom-made glaucoma care. 
 
Elevated intraocular pressure (IOP) is an established risk factor for glaucoma 
progression. Several other risk factors for progression have been identified with 
conflicting results.
1-14 These conflicting results might be attributed to variability in (1) the 
study design, (2) the study population, (3) the statistical approach applied, and (4) the 
outcome measure (progression definition) used. 
 
The aim of this study was to identify risk factors associated with visual field progression 
in glaucoma and to determine the influence of the statistical approach applied. For this 
purpose we compared different statistical approaches in a single dataset, using a single 
outcome measure. The statistical approaches were adopted from the Advanced Glaucoma 
Intervention Study (AGIS),
10 the Early Manifest Glaucoma Trial (EMGT),
6 and the 
Canadian Glaucoma Study (CGS).
1 The selected progression definition (outcome 
measure) was the Nonparametric Progression Analysis (NPA).
15 The dataset was the 
cohort of the Groningen Longitudinal Glaucoma Study (GLGS).
15;16 
 
PATIENTS AND METHODS 
 
Study population 
 
The present study was performed within the Groningen Longitudinal Glaucoma Study 
(GLGS), a prospective cohort study performed in a clinical setting. The objectives, 76 
 
methods, rationale and study design have been described earlier.
15;16 In short, all 875 
glaucoma patients and glaucoma suspects who visited our glaucoma outpatient service 
between July 1, 2000, and June 30, 2001, and who provided informed consent were 
included in an institutional review board–approved observational prospective follow-up 
using conventional perimetry, frequency doubling perimetry (FDT; Carl Zeiss Meditec AG, 
Jena, Germany) and laser polarimetry (GDx; Laser Diagnostic Technologies, San Diego, 
CA, USA). 
 
Out of the original 875 glaucoma patients and glaucoma suspects, 452 were classified as 
having glaucoma. Of the 452 glaucoma patients, the disease in 372 of them was 
classified using standard automated perimetry (Humphrey Field Analyzer [HFA]; Carl 
Zeiss Meditec Inc., Dublin, CA, USA). The Goldmann perimeter (Haag Streit AG, Bern, 
Switzerland) was used in 80 patients, who were excluded from the current analysis. Of 
the 372 patients classified using the HFA (for criteria see below), 221 patients who had 
undergone a follow-up period as measured from the last baseline test of at least 3 years 
and who had at least four reliable visual fields were included in the present study. 
 
Perimetry 
 
Perimetry was performed using the HFA 30-2 Swedish interactive threshold algorithm 
(SITA) fast strategy. An abnormal test result was defined as any one of the following: (1) 
a glaucoma hemifield test result outside normal limits, (2) a pattern standard deviation 
with P<0.05, or (3) three adjacent non-edge points with P<0.05 in the pattern deviation 
probability plot, with at least 1 point reaching P<.01 and with all points being on the 
same side of the horizontal meridian (LTG-P criterion).
17  A test result was considered 
unreliable if false-positive classifications exceeded 10% or if both false-negative 
classifications and fixation losses exceeded 10% and 20%, respectively. 77 
 
For glaucoma at baseline, two consecutive reliable test results had to be abnormal in at 
least one eye. Defects had to be in the same hemifield, and at least one depressed test 
point of these defects had to have exactly the same location on both fields. Moreover, the 
defects had to be compatible with glaucoma and without any other explanation. The first 
test result was discarded because of a learning effect. Therefore, at least three tests had 
to be performed at baseline before glaucoma could be diagnosed. During the follow-up 
period, perimetry was performed at a frequency of one test per year. In case of 
suspected progression or unreliable test results, clinicians were allowed to increase the 
frequency of testing. This was a subjective decision; no formal tools or rules were used. 
 
Progression detection 
 
The method used to identify progression was the Nonparametric Progression Analysis 
(NPA).
15 In this methods, reliable follow-up test results are compared with two reliable 
baseline test results. NPA is based on a nonparametric ranking
18 of mean deviation (MD) 
values. The MD values of the follow-up fields are compared with the worse MD value of 
the two baseline fields. If the MD of a follow-up field is better than or equal to the MD of 
the worse baseline field, the field is considered stable. If the MD of a follow-up field is 
worse than the MD of the worse baseline field, the change is considered outside the 
normal variation (that is, suspected progression). Possible progression is diagnosed if this 
change is confirmed once (deterioration in two consecutive fields) and likely progression 
if confirmed more than once (deterioration in three or more consecutive fields). Following 
a reading of suspected, possible, or likely progression, MD readings better than the worse 
baseline MD are disallowed; in that case, the patient’s condition is considered stable.
15 
This was done by assessing progression from the final field backwards, and in this way 
we circumvented the fact that normally the specificity of event-based progression 
detection algorithms decreases with increasing numbers of follow-up fields. In NPA, the 
two baseline fields divide the MD probability space of a patient a priori in three equal 78 
 
parts. Hence, if the eye is truly stable with no change in MD over time, the probability 
that the final field has an MD lower than that of both baseline fields is one-third. 
Therefore, the specificity of suspected progression in NPA is 0.67. Similarly, the 
specificities of possible (MD of the last two fields lower than that of both baseline fields) 
and likely progression (MD of the last three fields lower than that of both baseline fields) 
are 0.83 and 0.90, respectively.
18 
 
Risk Factors for Progression 
 
The possible risk factors for progression as documented in the GLGS from the very 
beginning were age, gender, myopia, cardiovascular disease, family history of glaucoma, 
pre-treatment IOP, IOP at baseline, mean IOP during follow-up, IOP fluctuation (standard 
deviation during follow-up), and HFA, FDT and GDx test results. All risk factors were 
recorded at baseline except for the mean IOP and IOP fluctuation during follow-up. The 
pre-treatment IOP was defined as the highest IOP ever measured prior to the study, 
before any treatment was started. Myopia was defined as a spherical equivalent of -4 D 
or more of myopia in at least one eye. Cardiovascular disease was defined in terms of 
whether cardiovascular medication was used or not. Family history of glaucoma was 
considered to be positive if the participants reported a history of glaucoma in their 
parents, siblings or offspring. All IOP measurements were performed with Goldmann 
applanation tonometry (Haag Streit AG, Bern, Switzerland). FDT at baseline was 
performed using the C-20 full-threshold mode. The HFA and FDT variable used was the 
MD, dichotomized as better or worse than the median value in the study population, 
being -6 dB for both devices. The GDx variable used was “The Number”.
16 New patients 
were scored as “untreated on inclusion” if treatment started after inclusion. This variable 
corrects for a possible bias resulting from the fact that some patients had not yet been 
treated at the time of inclusion. 
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Statistical Analysis 
 
Only one eye per patient was included. If a patient met the criteria with both eyes, a 
randomly chosen eye was included. Visual field progression was defined as having at 
least a possible progression at the end of the follow-up. Three different statistical 
approaches for risk factor analysis were applied, taken from three different glaucoma 
studies: AGIS,
10 EMGT
6 and CGS
1. 
 
In the AGIS,
10 associations between progression and various potential risk factors were 
assessed using multivariate logistic regression. Those factors that were associated with 
progression in univariate analyses (chi-square test, unpaired t test, or Wilcoxon rank sum 
test, depending on the type of data) at a P value of 0.20 or less were included in the final 
model. Furthermore, those clinically relevant variables such as age and gender that 
might potentially predict or confound the detection of progression were included. No 
selection other than univariate pre-selection was applied in the AGIS. In addition to this 
approach, we also added interaction terms and applied a stepwise variable selection. 
 
In the statistical approach of the EMGT,
6 Cox proportional hazard models with Breslow 
adjustment for ties in time to progression were used to evaluate the constancy of the 
hazard ratio throughout the follow-up time period. Univariate analyses of the risk factors 
for progression were explored using chi-square tests for categorical variables and t-tests 
for continuous variables. Variable selection was carried out in two steps. First, all 
variables significant in the univariate analyses at a P value of 0.20 or less were included 
in the model. Second, a stepwise variable selection algorithm was used to assess the 
best statistical fit. Furthermore, separate models were used to explore and identify those 
baseline and follow-up factors significantly associated with glaucoma progression. 
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In the statistical approach derived from the CGS,
1 risk factors for progression were first 
explored using Kaplan-Meier survival analyses with the log-rank test for the univariate 
analyses. Since selection of variables in the final model was based solely on a stepwise 
procedure and not on the results of univariate analyses, we did not report the results of 
these univariate analyses. As in the CGS, IOP was the only time-dependent variable in 
our study and therefore was analyzed as a covariate in the multivariate analysis. 
Variables were entered into a Cox Proportional hazards model in a forward stepwise 
analysis if their P value was 0.10 or less and if the hazards were judged to be 
proportional when examining the negative log plots of the survivor functions. Interaction 
terms were explored and included in the model if the partial likelihood ratio test indicated 
a better model fit. 
 
In order to assess the effect that the possible risk factors for glaucoma progression may 
have on the rate of progression (the MD slope, that is, the time derivative of MD), we 
performed a multiple linear regression analysis with rate of progression as the dependent 
variable and the factors that were found to be significantly associated with progression in 
the analyses described above as independent variables. 
 
All statistical analyses were performed using SAS 9.1.3 (SAS Institute Inc., Cary, NC, 
USA), except for the statistical approach employed from the AGIS where PASW Statistics 
17.0.2 (SPSS, Inc., Chicago, IL, USA) was used. Variables with a P value of 0.05 or less 
were considered statistically significant unless otherwise stated. 
 
 
RESULTS 
 
Table 1 shows the study population characteristics at baseline and during follow-up. The 
average follow-up duration (as measured from the last baseline field) was 5.3 years; on 81 
 
average 5.1 reliable follow-up fields were available (7.1 fields including baseline). The 
average MD at baseline was –9.4 dB; the average MD slope was -0.25 dB/years. 
According to the NPA algorithm, 89 of the 221 patients showed at least possible 
progression. 
 
Table 2 depicts the results of univariate risk factor analyses of all variables explored in 
the GLGS according to AGIS and EMGT statistical approach. Since variable selection in 
the CGS was solely based on a stepwise procedure, we did not present results for 
univariate analyses for the CGS statistical approach. Nine variables (age, gender, history 
of cardiovascular disease, HFA MD, FDT MD, GDx test result, baseline IOP, mean IOP 
during follow-up and IOP fluctuation) satisfied the criteria of the AGIS and EMGT 
statistical approaches. These variables were included in the logistic regression model and 
Cox proportional hazard model for the AGIS and EMGT approaches, respectively. 
 
Table 3 presents the results of the multivariate analyses with dependent variable NPA 
progression, using the AGIS, EMGT and CGS statistical approaches. With the AGIS 
approach, age was the only independent predictor of NPA progression with an odds ratio 
(OR) of 1.03 per year of increase in age. An interaction term between mean IOP and IOP 
fluctuation added to the model was not significant. Applying a stepwise variable selection 
resulted in a model that had the HFA MD (OR 2.72 for better versus worse than -6 dB), 
mean IOP during follow-up (OR 1.16 per mmHg increase) and age (OR 1.03) as 
independent risk factors for progression. With the EMGT and CGS approaches, three 
variables were found to be independent predictors of NPA progression. The FDT MD, 
baseline IOP and age increased the risk of NPA progression by 75% for better versus 
worse than -6 dB, 7% per mmHg increase in baseline IOP and 3% per year of increase in 
age, respectively in both approaches. None of the interaction terms used in the CGS 
approach were significant. 
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Table 4 shows the results of a multiple linear regression analysis with the rate of 
progression as the dependent variable, and with mean IOP during follow-up, HFA MD and 
age as independent variables. The rate of progression worsened (that is, became more 
negative) by 0.04 dB/year per mmHg of increase in mean IOP during follow-up and was 
0.18 dB/year more negative in patients with a baseline HFA MD of -6 dB or worse as 
compared to those with a better baseline MD. With baseline IOP in the model instead of 
mean IOP during follow-up, the rate of progression worsened by 0.02 dB/year per mmHg 
of increase in baseline IOP (95% CI -0.03 to -0.01 dB/year per mmHg; P=0.030). 
 
 
DISCUSSION 
 
IOP, baseline damage (as assessed with HFA or FDT) and age were found to be robust 
independent risk factors for glaucoma progression. The IOP variable that was significant 
depended on the statistical approach applied. 
 
Intraocular pressure 
 
Four IOP variables were included in our analyses. In all the analyses (except for the AGIS 
approach without stepwise selection) at least one of these variables was found to be a 
risk factor for glaucoma. This is not an unexpected finding, since IOP is a well-known risk 
factor for progression,
1;5;6;9;12;13 although there are reports that have failed to show such 
a relationship in normal tension glaucoma.
2;3 In our population, every mmHg increase in 
baseline or mean IOP increased the progression risk by 7% or 16 % respectively. This 
finding corroborates the increase of 12% per mmHg increase in average IOP during 
follow-up as reported in the EMGT
6 and the larger increase of 19% per mmHg increase in 
mean follow-up IOP as reported in the CGS
1. Our findings further buttress the importance 
of controlling the IOP of glaucoma patients. 83 
 
Using the AGIS statistical approach, none of the IOP variables were significant risk 
factors for progression, with IOP fluctuation closest to significance (P=0.091). After the 
additional stepwise variable selection, however, mean IOP during follow-up was a highly 
significant predictor of progression (P=0.003). If the analyses were repeated after 
excluding mean IOP during follow-up and including either baseline IOP or IOP fluctuation, 
the included IOP variable reached significance. Interestingly, the same phenomenon 
appeared both in the original AGIS analyses
10 and in a recent study in which IOP 
fluctuation was defined by the IOP range during follow-up.
8 These results would suggest 
that IOP fluctuation and either baseline IOP or average IOP during follow-up are not 
unrelated. In our study, IOP fluctuation was positively correlated with both the baseline 
IOP (r=0.40; P<0.001) and the mean IOP during follow-up (r=0.37; P<0.001). Because 
of the linear dependency among these variables, simultaneous inclusion in a model may 
lead to unstable coefficients of effect estimates. In order to rule out the possibility of 
collinearity, we carried out multicollinearity diagnostic statistics produced by linear 
regression analysis using Procedure Regression (PROC REG) with options variance 
inflation factor and tolerance in SAS.
19 None of the variance inflation factors was larger 
than 2.5 suggesting that there was no formal need to drop any IOP variable from the 
AGIS multivariate model as shown in Table 3. In addition, interaction terms were 
explored, but were found to be insignificant. 
 
Baseline disease stage 
 
Three methods of testing baseline disease stage were analyzed for their ability to predict 
glaucoma progression (HFA, FDT and GDx test results). We found HFA or FDT test results 
to be a significant risk factor for progression, but none of the final models showed FDT 
and HFA test results as both being significant risk factors in the same model. This is a 
plausible finding since FDT and HFA both measure functional visual field loss and, as to 
be expected, their scores were highly correlated (r=0.60; p<0.001). 84 
 
Since multi-collinearity diagnostic statistics showed that none of the variance inflation 
factors was larger than 2.5 (see above), both variables could be analyzed in the same 
model. 
 
An increased risk along with an increasing glaucoma stage was also reported in other 
studies.
5;7-9 The EMGT reported a HR of 1.55,
5 although in a later report the increase was 
not significant (HR 1.38, p=0.051).
6 In the CGS, using univariate analysis it seemed that 
a better baseline visual field was related to progression, but, in a multivariate regression 
analysis, this factor did not show significance.
1 The AGIS visual field score in the AGIS 
analyses showed no relationship with glaucoma progression.
10 It should be noted that the 
exclusion criteria in the AGIS, EMGT, and CGS were based, among other things, on visual 
field score, resulting in a narrowing of the baseline disease stage range. In our study, 
with a mean (SD; 95% central range) baseline MD of -9.4 dB (7.6 dB; -0.3 to -28.2 dB), 
such an exclusion criterion was not applied. 
 
Variable “The Number” from the baseline GDx was not found to be a significant risk factor 
for progression. This variable remained insignificant even if HFA and FDT were excluded 
from the analyses. Some prior studies have shown that a smaller neuro-retinal rim or an 
enlarged cup-to-disk ratio predicts progression,
4;7;12;14;20 although not all studies have 
reported this association.
11 
 
Finally, the assessment of disease stage as a risk factor requires a careful consideration 
of the sensitivity and specificity of the outcome measure as a function of disease stage - 
especially because the MD variability increases with disease stage. The specificity of the 
outcome measure used in this study, NPA, is independent of the variability whereas the 
sensitivity decreases with variability.
18 Despite this decreasing sensitivity with increasing 
variability (that is, with disease stage), we found disease stage to be an independent risk 
factor, suggesting that it is a robust finding. 85 
 
Hence, (perimetric) disease stage should be seen as a factor that requires careful 
consideration when making therapeutic decisions. 
 
Other factors 
 
Although many variables such as age, gender, myopia, family history of glaucoma, and 
the history of cardiovascular disease were explored, age was, in addition to IOP and 
disease stage, the only factor in our population that predicted progression in more than 
one analysis. For every yearly increment in age, the risk of progression increased by 3%. 
Several other investigators have reported a similar relationship between age and the 
progression of glaucoma,
1;5-8;10-12 whereas other studies were unable to confirm this 
association.
2;3;9;13;14 Family history and myopia seem to be associated with glaucoma
21-25 
but not with its progression.
1;3;5;11 Gender was a significant factor for progression in a 
minority of studies and this varied in terms of whether men
11 or women
1;3 had a greater 
risk. A history of cardiovascular disease
1;5;10 would not seem to be an independent 
predictor of glaucoma progression. 
 
Statistical Methodology 
 
The various statistical approaches used constitute a major setback when comparing 
different risk factor analysis studies. In order to explore the influence of the statistical 
technique used on the results of risk factor analysis, we compared the statistical 
approaches employed by the AGIS, the EMGT, and the CGS in a single dataset and with a 
single outcome measure. In the CGS, a pre-selection was not performed and the CGS 
approach was more conservative in its use of a P-value of 0.10 as the selection criterion 
for the stepwise selection procedure whereas EMGT and AGIS used a P-value of 0.20 in 
the univariate pre-selection. The CGS and EMGT used Cox regression in contrast to the 
logistic regression used by AGIS. 86 
 
The mathematical algorithms employed by these two models also differ. Interestingly, the 
answer to the ongoing discussion
26 of whether it is IOP fluctuation or another IOP 
variable that is the primary harmful factor in glaucoma progression depends, at least in 
our dataset, solely on the statistical approach used and which IOP variables were also 
analyzed in the same model. This underlines the importance of (1) a sound statistical 
design before the onset of the analyses to prevent “searching” for significance, (2) 
reticence in generalizing found risk factors, and (3) caution in the implementation of risk 
factors found in other reports. The significance of risk factors should always be seen in 
the light of previous (and later) reports. The risk factors found in our study are in 
agreement with the results of many other studies and this would tend to support the idea 
that they are indeed significant risk factors for glaucoma progression. 
 
We compared the statistical approaches of AGIS, EMGT and CGS, but not their outcome 
measures. The outcome measures used in these three studies were the AGIS scoring 
system in AGIS,
27 the Glaucoma Progression Analysis (GPA) in the EMGT,
28 and the 
Glaucoma Chance Probability (GCP) in the CGS.
29 The use of a single outcome measure 
enabled a more direct comparison of the statistical approaches. Moreover, the AGIS 
scoring system is not readily available and the GCP cannot be run on SITA test results. 
We compared NPA and GPA in an earlier study.
15 NPA had a fairly good agreement with 
GPA in early glaucoma, while NPA was more sensitive than GPA in patients with advanced 
glaucoma. The latter finding can be explained by the fact that GPA uses pattern deviation 
analysis. This makes the use of NPA more appropriate in our dataset with many patients 
with advanced disease. We repeated the risk factor analyses with outcome measure GPA. 
Similar associations were found but, as to be expected, the associations were less 
profound and did not reach significance in some analyses. 
 
Due to the finite number of visual field tests in our observational study, some cases with 
progression may have been misclassified as stable because confirmation was not yet 87 
 
performed at the end of the study. Similarly, some stable cases may have been 
erroneously classified as cases with progression because falsification after possible or 
likely progression was not yet performed. The misclassified cases could have resulted in 
conservative risk estimates. An inherent property of all event-based progression 
detection algorithms is that the specificity decreases with an increasing number of tests. 
We circumvented this limitation by disallowing MD readings better than the worse 
baseline MD following a reading of suspected, possible, or likely progression (see 
Methods section, progression detection subsection). The number of visual fields differed 
slightly between cases and controls (Table 1) and this might have influenced our results. 
We explored this issue by repeating all analyses with the number of visual fields added as 
a covariate. No significant changes were found. As mentioned in the Methods section, the 
GLGS is an observational study. Hence, as in all observational studies, some confounding 
by indication cannot be excluded. 
 
In conclusion, IOP, disease stage, and age seem to be significant independent risk factors 
for visual field progression in glaucoma. The results from risk-factor analyses may 
depend on the statistical approach applied. 88 
 
Table 1 Patient characteristics (mean with standard deviation between brackets unless 
stated otherwise) 
 
  All patients  NPA progression 
    Yes No 
Number of patients  221 (100%)  89 (40%)  132 (60%) 
      
Baseline      
Age (yr)  66.4 (12.3)  68.8 (11.5)  64.8 (12.6) 
Gender (% male)  55.2  48.3  59.8 
Family history (%)  16.9  20.7  14.4 
Myopia (%)  18.1  16.9  18.9 
Cardiovascular disease (%)  36.7  43.8  31.8 
HFA MD (dB)  -9.4 (7.6)  -10.0 (6.8)  -8.9 (8.0) 
FDT MD (dB)  -6.9 (5.5)  -7.8 (5.3)  -6.3 (5.7) 
GDx (The Number)  52.0 (24.1)  55.9 (23.4)  49.4 (24.3) 
IOP at baseline (mmHg)  16.1 (4.7)  17.0 (5.5)  15.5 (4.1) 
Untreated on inclusion (%)  10.9  13.5  9.1 
pre-treatment IOP (mmHg)  30.3 (9.5)  30.2 (10.0)  30.4 (9.2) 
      
Follow-up      
Follow-up duration (years)  5.3 (1.1)  5.3 (1.0)  5.3 (1.2) 
Number of visual fields  7.1 (1.9)  7.5 (1.7)  6.9 (2.0) 
HFA MD slope (dB/years)  -0.25 (0.56)  -0.69 (0.55)  0.04 (0.33) 
Mean IOP (mmHg)  14.9 (2.9)  15.5 (3.0)  14.5 (2.9) 
IOP fluctuation (mmHg)  2.8 (1.8)  3.2 (2.2)  2.5 (1.5) 
 
HFA = Humphrey Field Analyzer; MD = mean deviation; FDT = Frequency Doubling 
Technique perimeter; GDx = nerve fiber analyzer; IOP = intraocular pressure. 89 
 
Table 2 Univariate risk factor analyses for NPA progression according to the AGIS and 
EMGT statistical approaches 
 
Variables AGIS  approach  EMGT  approach 
  p-value p-value 
Baseline    
Age (yr)  0.008
†  0.017
^ 
Gender (% male)  0.091
‡  0.091
‡ 
Family history (%)  0.224
‡  0.224
‡ 
Myopia (%)  0.693
‡  0.693
‡ 
Cardiovascular disease (%)  0.069
‡  0.069
‡ 
HFA MD (% < -6 dB)  0.013
‡  0.013
‡ 
FDT MD (% < -6 dB)  0.017
‡  0.017
‡ 
GDx (The Number)  0.052
†  0.048
^ 
IOP (mmHg)  0.148
†  0.021
^ 
Untreated on inclusion (%)  0.303
‡  0.303
‡ 
pre-treatment IOP (mmHg)  0.762
†  0.906
^ 
    
Follow-up    
Follow-up Duration (yr)  0.960
†  NA 
Mean IOP (mmHg)  0.017
^  0.017
^ 
IOP fluctuation (mmHg)  0.045
†  0.005
^ 
 
HFA = Humphrey Field Analyzer; MD = mean deviation; FDT = Frequency Doubling 
Technique perimeter; GDx = nerve fiber analyzer; IOP = intraocular pressure; 
† = 
Wilcoxon rank sum test; 
‡ = Chi-square test; 
^ = Unpaired t test. 90 
 
Table 3 Odds ratios and hazard ratios for the logistic regression model (AGIS) and Cox 
proportional hazards models (EMGT, CGS), for dependent variable progression according 
to the NPA 
 
 Odds  ratio 
95% confidence 
interval 
P 
value 
AGIS approach      
Age (years)  1.03  1.00 – 1.06  0.044 
Gender (% male)  0.63  0.35 – 1.14  0.127 
Cardiovascular disease (%)  1.47  0.80 – 2.71  0.220 
HFA MD (% < -6 dB)  1.77  0.81 – 3.86  0.154 
FDT MD (% < -6 dB)  1.54  0.73 – 3.27  0.261 
GDx (The Number)  1.01  0.99 – 1.02  0.483 
Baseline IOP (mmHg)  1.03  0.94 – 1.12  0.569 
Follow-up duration (years)  1.01  0.78 – 1.32  0.918 
Mean IOP during follow-up (mmHg)  1.09  0.95 – 1.26  0.220 
IOP fluctuation (mmHg)  1.17  0.98 – 1.39  0.091 
      
AGIS approach with interaction 
term 
    
Age (years)  1.03  1.00-1.06  0.038 
Gender (% male)  0.63  0.34-1.14  0.123 
Cardiovascular disease (%)  1.50  0.81-2.78  0.197 
HFA MD (% < -6 dB)  1.78  0.81-3.88  0.149 
FDT MD (% < -6 dB)  1.53  0.72-3.24  0.269 
GDx (The Number)  1.01  0.99-1.02  0.509 
Baseline IOP (mmHg)  1.02  0.94-1.12  0.603 
Follow-up duration (years)  1.02  0.79-1.32  0.878 
Mean IOP during follow-up (mmHg)  1.04  0.85-1.27  0.696 
IOP fluctuation (mmHg)  0.85  0.34-2.07  0.712 
Mean IOP * IOP fluctuation  1.02  0.97-1.07  0.476 
      
AGIS approach with stepwise 
selection 
    
Age (years)  1.03  1.01 - 1.06  0.010 
HFA MD (% < -6 dB)  2.72  1.50 – 4.95  0.001 
Mean IOP during follow-up (mmHg)  1.16  1.05 - 1.29  0.003 
      
 
Hazard 
ratio 
95% confidence 
interval 
P 
value 
EMGT approach      
Age (years)  1.03  1.01 - 1.05  0.006 
FDT MD (% < -6 dB)  1.75  1.14 - 2.70  0.013 
Baseline IOP (mmHg)  1.07  1.02 - 1.11  0.010 
      
CGS approach      
Age (years)  1.03  1.01 - 1.05  0.006 
FDT MD (% < -6 dB)  1.75  1.14 – 2.70  0.013 
Baseline IOP (mmHg)  1.07  1.02 - 1.11  0.010 91 
 
HFA = Humphrey Field Analyzer; MD = mean deviation; FDT = Frequency Doubling 
Technique perimeter; GDx = nerve fiber analyzer; IOP = intraocular pressure. 
 
 
Table 4 Results of multiple linear regression analyses with rate of progression (mean 
deviation slope) as dependent variable 
 
 
Regression 
coefficient 
95% confidence 
interval 
P value 
(Intercept) 0.771  0.226 – 1.315 0.006 
HFA MD (% < -6 dB)  -0.179  -0.324 – -0.034 0.016 
Mean IOP during follow-up (mmHg)  -0.043  -0.067 – -0.019  <0.001 
Age (years)  -0.004  -0.010 - 0.001  0.136 
 
HFA = Humphrey Field Analyzer; MD = mean deviation; IOP = intraocular pressure. 92 
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ABSTRACT 
 
Objective: To determine the association between myopia and open-angle glaucoma. 
Design: Systematic review and meta-analysis of observational studies. 
Participants: Thirteen studies involving 48,161 individuals. 
Methods: Articles published between 1994 and 2010 were identified in PubMed, Embase 
and reference lists. Study specific odds ratios were pooled using a random effects model. 
Main Outcome Measures: Odds ratios with 95% confidence intervals of myopia as a 
risk factor for open-angle glaucoma. 
Results: Data from 11 population-based cross-sectional studies were included in the 
main analyses. The pooled odds ratio of the association between myopia and glaucoma 
based on 11 risk estimates was 1.92 (95% confidence interval 1.54 to 2.38). Based on 
seven risk estimates, the pooled odds ratios of the associations between low myopia 
(myopia up to -3 dioptres) and glaucoma and high myopia (-3 dioptres and more myopic) 
and glaucoma were 1.65 (1.26 to 2.17) and 2.46 (1.93 to 3.15), respectively. There was 
considerable heterogeneity among studies that reported an association between any 
myopia and glaucoma (I
2=53%) and low myopia and glaucoma (I
2=29%), but not for 
high myopia and glaucoma (I
2=0%). After omitting the studies that contributed 
significantly to the heterogeneity, the pooled odds ratios were 1.88 (1.60 to 2.20) for any 
myopia and glaucoma and 1.77 (1.41 to 2.23) for low myopia and glaucoma. 
Conclusions: Individuals with myopia have an increased risk of developing open-angle 
glaucoma. 97 
 
INTRODUCTION 
 
Myopia, or short-sightedness, affects about 1.6 billion people worldwide and the 
prevalence is expected to rise to 2.5 billion by the year 2020.
1-2 Myopia has long been 
identified as a risk factor for open-angle glaucoma (OAG).
3-6 OAG is an irreversible eye 
disease responsible for approximately 12% of global blindness, which is second to 
cataract.
7 It is largely unknown why myopia increases the risk of OAG. Myopic eyes have 
longer axial lengths and vitreous chamber depths,
8-9 and eyes with an increased axial 
length seem to have a greater deformability of the lamina cribrosa. This might contribute 
to a higher susceptibility to glaucomatous optic disc changes.
8,10 
 
There is conflicting evidence concerning the range of refractive error important for OAG. 
While some studies have reported an association with any myopia,
11-14 others have found 
the relationship only in individuals with high myopia.
15-18 A better understanding of the 
role of the magnitude of the refractive error is clinically important from the point of view 
of individualized risk management, amongst others. 
 
The reported associations between myopia and OAG are predominantly based on the 
results of observational studies. However, to the best of our knowledge, a systematic 
approach to quantitatively combine the results of all available studies evaluating the 
association between myopia and OAG does not exist. The aim of this review is to 
examine the magnitude of the association between myopia and OAG by systematically 
identifying and quantitatively combining all available and relevant observational studies. 
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METHODS 
 
Search strategy 
 
Two of the authors (MMV and FGJM) independently conducted a systematic search of 
Pubmed and Embase up to 27 October 2010 in accordance with the MOOSE consensus 
statement.
19 The search terms used in PubMed included (("myopia"[MeSH Terms] OR 
"myopia"[All Fields]) OR myopic[All Fields] OR ("refractive errors"[MeSH Terms] OR 
("refractive"[All Fields] AND "errors"[All Fields]) OR "refractive errors"[All Fields] OR 
("refractive"[All Fields] AND "error"[All Fields]) OR "refractive error"[All Fields])) AND 
(OAG[All Fields] OR POAG[All Fields] OR ("glaucoma"[MeSH Terms] OR "glaucoma"[All 
Fields])) AND (("risk factors"[MeSH Terms] OR ("risk"[All Fields] AND "factors"[All 
Fields]) OR "risk factors"[All Fields] OR ("risk"[All Fields] AND "factor"[All Fields]) OR 
"risk factor"[All Fields]) OR ("risk factors"[MeSH Terms] OR ("risk"[All Fields] AND 
"factors"[All Fields]) OR "risk factors"[All Fields]) OR determinant[All Fields] OR 
determinants[All Fields] OR ("association"[MeSH Terms] OR "association"[All Fields]) OR 
associated[All Fields]). For Embase we used (myopia/exp OR myopia OR myopic OR 
r e f r a c t i v e )  A N D  ( e r r o r / e x p  O R  e r r o r )  A N D  ( O A G  O R  P O A G  O R  g l a u c o m a / e x p  O R  
glaucoma) AND (((((risk/exp OR risk) AND factor) OR risk/exp OR risk) AND factors) OR 
determinant OR determinants OR association/exp OR association OR associated). 
 
Retrieved studies from both Pubmed and Embase were imported into Refworks (version 
1.0; Refworks, Bethesda, Maryland, USA) where duplicate articles were manually deleted. 
Titles and abstracts of the remaining studies were independently scanned by two authors 
(MWM and MMV). The extracted studies were compared and inconsistencies were 
resolved by consensus. The full texts of the remaining studies were then read to 
determine if they met our inclusion criteria. In addition, the reference lists from all 
identified studies were examined. 99 
 
Inclusion and exclusion criteria 
 
S t u d i e s  w e r e  i n c l u d e d  i f  t h e y  ( i )  r e p o r t e d  m y o p i a  a s  c o v a r i a t e ,  ( i i )  h a d  O A G  a s  t h e  
outcome measure, and (iii) reported a measure of the association either as odds ratio 
( O R )  o r  h a z a r d  r a t i o  ( H R )  w i t h  9 5 %  c o n f i d e n c e  i n t e r v a l  ( C I ) ,  o r  a l l o w e d  f o r  t h e  
calculation of it from the raw data presented in the article. We excluded (i) studies 
involving secondary glaucoma or angle-closure glaucoma, (ii) studies published in non-
English language, and (iii) studies without a clear-cut definition of myopia and or detailed 
description of OAG assessment. When multiple publications from the same study 
population were available, we checked for duplicate analysis and included only the most 
recent publication. 
 
Data extraction and quality assessment 
 
For each study, the following characteristics were extracted: (i) last name of first author, 
(ii) year of publication, (iii) study design, (iv) race/ethnicity of the study population, (v) 
number of subjects in the analysis, (vi) age range of subjects included in the studies, 
(vii) case definition of OAG, (viii) definition of myopia, (ix) the effect estimate(s), and (x) 
which confounding factors was adjusted for. The study quality was assessed with the tool 
described by Sanderson et al.
20 The variables examined included the methods for 
selecting study participants, methods for measuring exposure (myopia) and outcome 
variable (OAG), design-specific sources of bias (excluding confounding), methods for 
controlling confounding, statistical methods (excluding control of confounding), and 
conflict of interest. 
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Statistical Analysis 
 
The fully-adjusted study specific ORs were combined to estimate the pooled OR with 95% 
CI using the random effects model. The random effects model was chosen because it 
accounts for both within-study and between-study variability, and we expected significant 
heterogeneity among the included studies. For the Andhra Pradesh study,
21 that reported 
results for urban and rural cohorts separately, we combined the two ORs and 
subsequently included the pooled OR in the meta-analysis. Most of the studies included in 
our meta-analysis reported both an OR for any myopia and ORs after stratification. For 
studies that only reported stratified ORs, we pooled the ORs to obtain an overall estimate 
for any myopia. Following the stratification as used in the majority of the studies, myopia 
was stratified in low myopia, defined as myopia with a spherical equivalent refractive 
error up to -3 dioptres, and high myopia, defined as a spherical equivalent refractive 
error of -3 dioptres and more myopic. 
 
Statistical heterogeneity among studies was evaluated using I
2  Statistic. I
2 is the 
percentage of the total variation across the studies that is due to heterogeneity.
22 Values 
of less than 24%, 25-49%, 50-74% and 75% or above denote no, low, moderate and 
high heterogeneity, respectively.
23 Heterogeneity due to study design was avoided by 
restricting the main analyses to population-based cross-sectional studies only. 
Furthermore, we performed a sensitivity analysis which investigates the contribution of 
each study to the heterogeneity by sequentially omitting one study and reanalysing the 
pooled estimate for the remaining studies.
24 Publication bias was evaluated with the use 
of Egger regression asymmetry test and the Begg’s test.
25,26 All statistical analyses were 
performed with Stata version 11.1 (StataCorp, College Station, Texas, USA). A two-sided 
p value less than 0.05 was regarded as significant for all analyses. 
 
 101 
 
RESULTS 
 
Figure 1 shows the selection process. The literature search yielded 1176 articles; 527 
from PubMed and 649 from Embase, of which 70 were reviewed in full text. After a 
thorough review, 13 studies met the inclusion criteria for this meta-analysis.
21,27-38 All 
studies were population based; 11 cross-sectional,
28-37 one case-control,
27 and one 
longitudinal cohort study.
38 Six studies were conducted in Asia,
21,32-36 two in North 
America,
31,37 two in Australia,
29-30 two in Europe,
27,38 and one in Barbados.
28 Table 1 
(available at http://aaojournal.org) presents the characteristics of the included studies. 
The studies were published between 1994 and 2010 and comprised a total study 
population of 48,161 individuals. The definition of OAG and myopia varied across studies. 
Three studies included an increased IOP in their case definition of OAG,
27,30,31 one study 
included the family history of OAG,
30 and two studies included a history of glaucoma 
treatment.
27,31 Seven studies included the cup-disk ratio (a measure of optic nerve 
damage) with different cut-off values;
21,27,29-32,35 all studies included a visual field 
test.
21,27-38 Seven of the 13 included studies reported risk estimates for low and high 
myopia separately.
29,31-34,36,37 
 
The pooled OR for all 13 studies was 1.93 (95% CI 1.57 to 2.37; I
2=55%; P=0.01). To 
avoid heterogeneity due to study design, two studies (one case-control and one cohort 
study) were subsequently excluded from the analyses.
27,38 Figure 2 presents the 
multivariate ORs for each study separately and for the 11 cross-sectional studies 
combined. The pooled OR of the association between any myopia and OAG was 1.92 
(95% CI 1.54 to 2.38). There was a statistically significant heterogeneity among the 11 
cross-sectional studies (I
2=53%; P=0.02). Sensitivity analysis showed that the Andhra 
Pradesh study and the Beijing study substantially influenced the pooled OR. After 
excluding these two studies, the pooled OR was 1.88 (95% CI 1.60 to 2.20) with no 
evidence of heterogeneity (I
2=7%; P=0.38). 102 
 
From the 11 included studies, seven studies reported risk estimates for both low and high 
myopia. Figure 3 shows the ORs of the association between low myopia and OAG. The 
pooled OR was 1.65 (95% CI 1.26 to 2.17) with a low heterogeneity (I
2=29%; P=0.21). 
Sensitivity analysis showed that the Beijing study substantially influenced the pooled OR. 
After excluding this single study, the pooled OR was 1.77 (95% CI 1.41 to 2.23) with no 
evidence of heterogeneity (I
2=0%; P=0.66). Figure 4 shows the ORs of the association 
between high myopia and OAG. The pooled OR was 2.46 (95% CI 1.93 to 3.15) with no 
heterogeneity (I
2=0%; P=0.45). There was no evidence of publication bias as indicated 
by a non-significant Egger test (P=0.25) and Beggs’s test (P=0.13). 
 
 
DISCUSSION 
 
The findings from this meta-analysis indicate that individuals with myopia have a roughly 
doubled risk of developing OAG in comparison with individuals without myopia. The 
pooled ORs were 2.46 (95% CI 1.93 to 3.15) for high myopia and 1.77 (95% CI 1.41 to 
2.23) for low myopia, with a cut-off value of -3 dioptres. 
 
Although the point estimate of the pooled OR of high myopia was larger than that of low 
myopia, the difference was small. A more pronounced dose-response relationship would 
have reinforced the association between myopia and OAG. The apparent absence of a 
clear dose-response relationship might be the consequence of the population-based 
design of the included studies. Myopia beyond, for example, -10 dioptres is seen on a 
regular basis in a clinical setting. In a population-based sample, however, most 
participants with high myopia have a refractive error between -3 and -4 dioptres, and 
values beyond -5 dioptres are rare.
39-41 
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The observed heterogeneity among the included cross-sectional studies was explained by 
the Andhra Pradesh study and the Beijing study. Although these studies, in contrast to 
the majority of the included studies, were conducted in Asia and included both urban and 
rural cohorts, the disparate results of these two studies in this meta-analysis remain 
unclear. Two studies, Ponte et al.
27 and Czudowska et al.
38 were omitted beforehand 
because of different study designs. In their case-control study, Ponte et al. reported an 
association between myopia (-1.5 dioptres and more myopic) and OAG with an OR of 
5.56 (95% CI 1.85 to 16.67). In their population based cohort study, Czudowska et al. 
reported an association between high myopia and incident OAG with a HR of 2.31 (95% 
CI 1.19 to 4.49); the association between low myopia and incident OAG was not 
significant (HR 1.16; 95% CI 0.72 to 1.88). These studies confirm the presence of an 
association between myopia and OAG. 
 
Strengths of this meta-analysis include the population-based design of the included 
studies and their high response rates, ranging from 78.7% to 97.3%. The population-
based design is likely to minimize the possibility of selection bias. Even if myopes would 
be preferentially ascertained (because they might be more eager to participate in an eye 
study), this could bias the estimate of the prevalence of myopia, and thus of the 
prevalence of glaucoma, but not of the association between myopia and glaucoma. 
Selection bias may be present in clinical case-control studies, for example because 
individuals with myopia tend to visit an optician or ophthalmologist more often than 
individuals with emmetropia, and therefore are more likely to be diagnosed with OAG. An 
increased optician or ophthalmologist visit frequency amongst myopic subjects, however, 
may also introduce a bias in population-based studies: the treatment of a timely detected 
ocular hypertension may prevent or delay the development of OAG. By adjusting the 
analyses for the intraocular pressure, as is done in most studies (Table 1; last column; 
available at http://aaojournal.org), the effect of this bias should have been minimised as 
much as possible. 104 
 
Moreover, if this bias would dominate the results, a protective effect of myopia would 
have been found. Residual or unknown confounding could be present in the included 
studies and thus in the pooled analysis. Inadequate control for confounding factors may 
bias the results towards both underestimation and overestimation of ORs. 
 
The way patients were diagnosed with myopia and OAG differed between the included 
studies and therefore some diagnostic bias might be present. As can be seen in Table 1 
(available at http://aaojournal.org), the cut-off point between low and high myopia 
varied between -3 and -4 dioptres (-3 dioptres in most studies); the cut-off point 
between emmetropia and (low) myopia varied between -0.01 and -1.5 dioptres (-0.5 or -
1 dioptres in most studies). The OAG definition was based on a combination of 
glaucomatous visual field loss and optic disc abnormalities in most studies, with various 
criteria and cut-off points. Visual field defects as well as anomalous appearing optic discs 
have been reported in persons with myopia.
42-44 This could have resulted in either an 
over-classification or an under-classification of OAG in persons with myopia because of 
the difficulties in classifying the optic disc and the visual field in some myopic eyes. This 
misclassification of OAG may have biased the reported effect estimate of the association 
between myopia and OAG. Moreover, persons with myopia have – on average – slightly 
larger optic discs and, related to that, larger excavations.
43-45 As most OAG definitions 
relied on the size of the excavation without adjusting for the size of the optic disc, this 
may have resulted in an overestimation of the presence of OAG in participants with 
myopia. Such an overestimation could partially explain the reported increased risk. 
However, the fact that the only longitudinal study yielded roughly the same results 
suggests that all these potential sources of misclassification did not produce a substantial 
bias (compared to cross-sectional data, incident data should be less prone to 
misclassification of abnormal or large optic discs and myopic visual field loss).
38 Ponte et 
al.
27 required their controls to have very small optic disc excavations. This requirement 
may have resulted in an underrepresentation of myopia amongst the controls (see 105 
 
above), and this might explain their large odds ratio. Their wide confidence interval, 
however, precludes firm conclusions. 
 
Finally, the major setback of published studies and of meta-analyses of published studies 
in general is publication bias. Publication bias may be an issue because studies that 
report statistically significant results are more likely to get published than studies that 
report non-significant results and this could have distorted the findings of our meta-
analyses.
46 However, Egger regression asymmetry test and the Begg’s test suggested no 
evidence of publication bias in our study. 
 
In conclusion, findings from this meta-analysis indicate that subjects with both low 
myopia and high myopia have an increased risk of developing OAG. This should be taken 
into account when it comes to individualized risk management in, for example, screening 
or treatment decisions. Future research is warranted to determine the association 
between myopia and OAG in severe myopia (which is rare in population-based samples) 
and to elucidate the pathophysiological mechanism underlying the association between 
myopia and OAG. 106 
 
Table 1. Characteristics of the included studies 
 
          
Source Study  design  Race/ 
Ethnicity 
Study population  Age Definition 
of glaucoma 
Definitions of 
myopia 
(SEq in dioptres) 
Odds Ratio 
(95%CI) 
Adjusted 
covariates 
Ponte et al. 
The Casteldaccia Eye 
Study (1994)
27 
Population-based 
case-control study 
White 264  ≥40 Cases:  IOP  ≥24 
mmHg, history of 
treated glaucoma, 
GVFL. Controls: IOP 
≤20 mmHg, CD-ratio: 
0-0.2, pink discs, no 
aphakia or 
pseudophakia, no 
history of (treated) 
glaucoma 
<-1.5*  5.6(1.9-16.7)*  Age, gender, ocular 
steroids or antibiotics 
use, shallow anterior 
chamber, DM, 
hypertension, iris 
texture, myopic 
macular degeneration 
Wu et al. 
The Barbados Eye Study (1999)
28 
 
Population-based 
cross-sectional 
Black  4036  40-84  GVFL, optic disc 
abnormalities 
<-0.5* 1.5(1.1-2.0)*  Age,  gender,  SES, 
lens opacity 
Mitchell et al. 
The Blue Mountains Eye Study 
(1999)
29 
Population-based 
cross-sectional 
White 3654  49-97  GVFL,  CD-ratio  ≥0.7 
or asymmetry ≥0.3 
≤-1.0* 
 
≤-1.0 to >-3.0† 
 
≤-3.0‡ 
2.4(1.5-4.0)* 
 
2.3(1.3-4.1)† 
 
3.3(1.7-6.4)‡ 
Age, gender, family 
history, DM, steroid 
use, typical migraine 
history, hypertension, 
pseudo-exfoliation 
Weih et al. 
Visual Impairment Project (2001)
30 
Population-based 
cross-sectional 
Diverse 4498  ≥40 IOP  ≥22mmHg, GVFL, 
CD-ratio  ≥0.8 or 
asymmetry  ≥0.4, 
family history of 
glaucoma 
≤-0.5* 1.6(0.9-6.7)*  Age,rural  residence 
and family history 
Wong et al. 
The Beaver Dam Eye Study 
(2003)
31 
Population-based 
cross-sectional 
White 4670  43-86  GVFL,  IOP  ≥22 mmHg, 
CD-ratio  ≥0.8 or 
asymmetry  ≥0.2, 
history of glaucoma 
treatment 
≤-1.0* 
 
≤-1.0 to >-3.0† 
 
≤-3.0‡ 
1.6(1.1-2.3)* 
 
1.6(1.1-2.4)† 
 
1.5(0.8-2.6)‡ 
Age, gender 
Ramakrishnan et al. 
The Aravind Comprehensive Eye 
Survey (2003)
32 
Population-based 
cross-sectional 
Indian 5150  ≥40 GVFL,  CD-ratio  ≥0.9 
or asymmetry ≥0.3, 
optic disc 
abnormalities, normal 
gonioscopy 
<-0.5* 
 
Mild 
 
Moderate 
 
Severe 
2.8(1.7-4.6)*^ 
 
2.9(1.3-6.9)† 
 
2.1(1.0-4.6)‡ 
 
3.9(1.6-9.5)‡ 
Age, gender, DM, 
hypertension, 
pseudo-exfoliation 
Suzuki et al. 
The Tajimi Study (2006)
33 
Population-based 
cross-sectional 
Japanese 2874  ≥40 optic  disc 
abnormalities, 
perimetric results, 
other ocular findings 
<-1.0* 
 
<-1.0 to >-3.0† 
 
≤-3.0‡ 
2.2(1.5-3.3)*^ 
 
1.9(1.0-3.3)† 
 
2.6(1.6-4.4)‡ 
Age, IOP 
Xu et al. 
The Beijing Eye Study (2007)
34 
Population-based 
cross-sectional 
Chinese 4319  ≥40 optic  disc 
abnormalities, GVFL 
<-0.5* 
 
Low to moderate 
3.8(2.1-6.7)*^ 
 
0.6(0.3-1.5)† 
Age, IOP 107 
 
 
Marked or high 
 
4.7(1.8-12.5)‡ 
Casson et al. 
The Meiktila Eye Study (2007)
35 
Population-based 
cross-sectional 
Diverse 1997  ≥40 CD-ratio  ≥0.7 or ≥0.6 
with asymmetry ≥0.3, 
reduced NRRW, GVFL, 
>90
0 of TM visible 
<-0.5*  2.7(1.0-7.5)*  Age, IOP, AL 
Garudadri et al. 
The Andhra Pradesh Eye Disease 
Study (2010)
21 
Population-based 
cross-sectional 
Indian 3724  ≥40 Asymmetrical  CD-
ratio, NRRW reduced 
to 0.1, GVFL 
≤-0.5* 1.0(0.6-1.6)*^ 
 
Age, DM, gender, IOP, 
hypertension 
Perera et al. 
The Singapore Malay Eye Study 
(2010)
36 
Population-based 
cross-sectional 
Malay 3109  40-80  optic  disc 
abnormalities, GVFL 
<-0.5* 
 
<-0.5 to ≥-4.0† 
 
<-4.0‡ 
1.8(0.9-3.7)*^ 
 
1.3(0.6-2.7)† 
 
2.8(1.1-7.4)‡ 
Age, gender, IOP, 
education, height, 
CCT, hypertension, 
HbA1c 
Kuzin et al. 
The Los Angeles Latino Eye Study 
(2010)
37 
Population-based 
cross-sectional 
Latino 5927  ≥40 optic  disc 
abnormalities, GVFL 
≤-1.0* 
 
≤-1.0 to >-3.0† 
 
≤-3.0‡ 
1.8(1.2-2.8)* 
 
1.6(0.9-2.6)† 
 
2.0(1.1-3.7)‡ 
Age, IOP, DM, gender, 
family history, NO, CP 
Czudowska et al. 
The Rotterdam Study (2010)
38 
Population-based 
cohort study 
White 3939  ≥55 Incident  GVFL  ≤-0.01* 
 
≤-0.01 to >-4.0† 
 
≤-4.0‡ 
1.5(1.1-2.0)*^# 
 
1.2(0.7-1.9)†# 
 
2.3(1.2-4.5)‡# 
Age, gender, IOP, IOP 
treatment, family 
history, baseline GON 
 
Abbreviations: SEq = spherical equivalent; CI= confidence interval; IOP = intraocular pressure; GVFL = glaucomatous visual field loss; CD = cup disk; 
DM = diabetes mellitus; SES = social economic status; NRRW = neuro retinal rim width; TM = trabecular meshwork; AL = axial length; CCT = central 
corneal thickness; HbA1c = hemoglobin A1c; NO = nuclear opacification;CP = corneal power; GON = glaucomatous optic neuropathy; * = any myopia; † 
= low myopia; ‡ = high myopia; ^ = calculated from data contained in the article; # = hazard ratio. 108 
 
Figure 1  Flow diagram showing the selection process for inclusion of studies in the 
meta-analysis 
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Figure 2 Forest plot of risk estimates of the association between myopia and open-angle 
glaucoma 
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Figure 3 Forest plot of risk estimates of the association between low myopia myopia and 
open-angle glaucoma 
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Figure 4 Forest plot of risk estimates of the association between high myopia myopia 
and open-angle glaucoma 
 
Overall (I-squared = 0.0%, p = 0.446)
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Abstract 
 
Medications administered systemically can cause a substantial rise in the intraocular 
pressure (IOP) and thus induce open-angle glaucoma (OAG). Well-known and extensively 
studied medications with this side effect are corticosteroids. The anti-neoplastic agents 
docetaxel and paclitaxel have also been reported to have this side effect but this 
suspicion appeared to be based on a single case report. Other systemic medications are 
associated with a lowering of the IOP. Drugs that fall into this category include carbonic 
anhydrase inhibitors and cannabinoids. Several anti-hypertensive medication classes 
have been reported to be related to OAG, both in a protective and a harmful manner, and 
at least partially through IOP-independent mechanisms. Ginkgo biloba extract has been 
reported to increase ocular blood flow and cholesterol-lowering drugs appear to reduce 
the risk of OAG and slow down its progression – presumably through an IOP-independent 
mechanism. In addition, we will also report findings about the effect of antithrombotics 
and estrogens on OAG. The objective of this review is to present and evaluate the current 
state of knowledge of the effect of systemic medications on OAG. 117 
 
Introduction 
 
Although the beneficial effects of systemic medications are numerous, they can also 
trigger undesirable side effects. Undesirable side effects have been documented for 
almost all medications on various body tissues and organs including the eye.
1-7 
Unwarranted ocular effects may progress and cause irreversible damage, resulting in 
visual impairment and blindness.
7,8 Corticosteroid-induced glaucoma is an example of 
such an adverse effect of medications in which patients develop an elevated intraocular 
pressure (IOP), optic neuropathy and visual field defects indistinguishable from open-
angle glaucoma (OAG).
2,9 OAG, the eye disease targeted in this review, is responsible for 
approximately 12% of global blindness, which is second to cataract.
10 
 
Traditionally, the management of OAG is targeted towards the reduction of the IOP (the 
only modifiable risk factor) and systemic medications that cause an increase in IOP are 
the most obvious medications that have OAG as a side effect. The corticosteroids 
mentioned above are the most well-known example of medications that can cause a 
substantial rise in IOP and thus induce OAG.
11,12 Some patients develop OAG without a 
clearly elevated IOP. Here, individual variation of the susceptibility of the optic nerve may 
play a role. Also, some factors influence the course of the disease without altering the 
IOP, suggesting a vascular component or a role for neuroprotection.
13-16 An example is 
the IOP-independent protective effect of statins.
17 
 
Despite its public health relevance, reviews summarizing evidence-based information 
about OAG and its association with systemic medications mainly focus on steroid-induced 
OAG and angle closure glaucoma.
11,18-20 The objective of this systematic review is to 
present and evaluate the current state of knowledge of the effects of systemic 
medications on OAG. 
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Search strategy 
 
Articles assessed for this review were identified by an electronic search of PubMed and 
Embase, for English language studies from the inception of the databases till March 2011. 
We reviewed all relevant articles related to glaucoma and systemic medications, 
glaucoma and systemic diseases, and glaucoma medications, by using in PubMed the 
search term ("glaucoma"[MeSH Terms] OR "glaucoma"[All Fields]) AND systemic[All 
Fields] AND ("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All 
Fields] AND "preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR 
"medications"[All Fields]) AND ("glaucoma"[MeSH Terms] OR "glaucoma"[All Fields]) AND 
systemic[All Fields] AND ("disease"[MeSH Terms] OR "disease"[All Fields] OR 
"diseases"[All Fields]) AND ("glaucoma"[MeSH Terms] OR "glaucoma"[All Fields]) AND 
("pharmaceutical preparations"[MeSH Terms] OR ("pharmaceutical"[All Fields] AND 
"preparations"[All Fields]) OR "pharmaceutical preparations"[All Fields] OR 
"medications"[All Fields]) and in Embase systemic AND diseases AND glaucoma/exp AND 
medications. For those medications found with this strategy, a further systematic search 
was performed in the same databases. For example, the search term used for 
“cannabinoids” in Pubmed was (("cannabinoids"[MeSH Terms] OR "cannabinoids"[All 
Fields] OR "cannabinoid"[All Fields]) AND ("glaucoma"[MeSH Terms] OR "glaucoma"[All 
Fields])) AND ("humans"[MeSH Terms] AND English[lang]) and in Embase 
'cannabinoids'/exp AND 'glaucoma'/exp AND [humans]/lim AND [english]/lim AND 
[embase]/lim .In addition, the reference lists from all identified studies were examined. 
Duplicate studies and studies reporting on angle-closure glaucoma were excluded. 
Systemic mediactions identified with this strategy were corticosteroids, docetaxel and 
paclitaxel, anti-hypertensive medications, antithrombotics, carbonic anhydrase inhibitors, 
cannabinoids, Ginko biloba extract, cholesterol-lowering drugs, and estrogens. 
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Corticosteroids 
 
Corticosteroids have widespread clinical application and their anti-inflammatory 
properties make them also highly potent agents for ocular diseases.
21 Since their 
introduction to ophthalmology in the 1950s,
22 various ocular adverse effects including 
corticosteroid-induced glaucoma
23 and cataract
24 have been reported related to the 
topical application of steroids. The mechanism by which corticosteroids elevate the IOP is 
thought to be due to the accumulation of undegraded extracellular matrix material in the 
trabecular meshwork, thus impeding the outflow channels and increasing the outflow 
resistance.
25,26 Individuals who develop an increase in IOP after steroid therapy are 
referred to as steroid responders.
27-29 Glaucoma with a clinical picture similar to that of 
primary OAG (POAG) may develop if the IOP elevation is of sufficient magnitude and 
duration: steroid-induced glaucoma. In the literature, several risk factors have been 
suggested for being a steroid responder. They include the presence of POAG or its family 
history, age, diabetes mellitus, high myopia and rheumatoid arthritis.
30-39 Of these 
factors, the positive family history, age and high myopia are established risk factors for 
POAG as well.
33,40,41 Thus far, evidence supporting connective tissue diseases such as 
rheumatoid arthritis to be a risk factor for steroid responsiveness was mainly reported in 
case studies and case series and the results were inconclusive. For example, Bernstein 
reported an elevated IOP in 48 patients taking oral steroids for rheumatoid arthritis or 
other collagen diseases when compared to age and sex matched controls not taking 
steroids.
42 Although they attributed this to the systemic steroids, none of the controls 
had rheumatoid arthritis or other collagen diseases. In contrast, Belousna reported a 
lower IOP in 60 patients taking systemic steroids for collagen diseases when compared to 
the normal individual.
43 However, there was no report on the IOP of patients with 
collagen diseases who were not on steroid therapy. Gaston et al reported a higher 
incidence of steroid responsiveness than would be expected in a normal population in 34 
patients with connective tissue diseases who were on steroid therapy.
44 They suggested 120 
 
that the damage to the trabecular meshwork as a possible mechanism of steroid 
responsiveness. 
 
For ophthalmologists, the topical corticosteroids are the most commonly prescribed class 
of steroids, and presumably the class most clearly related to the steroid response and to 
steroid-induced glaucoma. The question is on how far other classes of steroids, being the 
oral, inhaled and nasal steroids, and the steroid ointments, may induce steroid-induced 
glaucoma as well. Till date, most information about corticosteroid-induced glaucoma has 
been based on case reports. In addition to these case reports, Garbe et al. published two 
studies evaluating the association between the use of oral, inhaled, and nasal steroids 
and the risk of ocular hypertension or OAG in a health insurance database.
45,46 In these 
large case control studies, the use of inhaled and nasal steroids was not associated with 
an increased risk of ocular hypertension or glaucoma. However, they found an association 
in a subgroup of subjects with a prolonged administration of high doses of inhaled 
steroids (odds ratio [OR] 1.44; 95% confidence interval [CI] 1.01-2.06).
45 Furthermore, 
the use of oral steroids was shown to increase the risk of ocular hypertension or OAG (OR 
1.41; 95% CI 1.22-1.63).
46 Mitchell et al. evaluated the association between the use of 
ophthalmic steroids, oral steroid and inhaled steroids and the risk of an elevated IOP or 
OAG in a cross-sectional population based study.
47 In this study there was only an 
association between inhaled steroid use and the presence of either OAG or elevated IOP 
in persons with a positive family history of glaucoma (OR 2.6; 95%CI 1.2-5.8). The use 
of oral steroids or ophthalmic steroids was not associated with an elevated IOP or OAG. 
Haeck et al. evaluated the association between the use of topical corticosteroids and the 
development of glaucoma and cataract. This retrospective study included 88 atopic 
dermatitis patients of whom 37 used topical steroids on their eyelids and periorbitally for 
an average duration of 4.8 years. In this study, the application of topical corticosteroids 
was not associated with the development of glaucoma or cataract in their study 
population.
48 121 
 
In a prospective population-based cohort study, we recently evaluated the association 
between all classes of steroids, being ophthalmic, inhaled, oral and nasal steroids and 
steroid ointments, and the 10-year risk of OAG in 3939 participants aged 55 years and 
older.
49 In this study, the use of any class of steroids was not associated with the 
incidence of OAG. In addition, we performed a systematic review of the literature to 
identify all published case reports regarding steroid induced glaucoma. Table 1 
summarizes the results.
50-90 The review yielded 41 publications together reporting 74 
cases.
50-90 The median age of these cases was 32 years, with a range from 3 weeks to 80 
years. In the 74 cases, the OAG was presumed to be caused by ophthalmic steroids in 38 
cases,
51-55,59,65,66, 72,78-80,84-87,89,90 by inhaled steroids in one case,
71 by nasal steroids in 
two cases,
73 by oral steroids in nine cases,
52,56,69,76,81-83 and by steroid ointments in 31 
cases.
57-64,67-70,74,77,86-88,90. Myopia was reported as a risk factor in seven 
cases,
51,56,57,65,77,85,87 a positive family history of glaucoma in eight cases,
51-53,57,58,62,75,85 
diabetes mellitus in two cases,
51,73 and hypertension in one case.
76 
 
In the systematic review of published case reports, the most obvious finding was that the 
median age was 32 years and 81% of the identified cases were younger than the 
youngest age of 55 years of our study cohort. OAG before the age of 55 years is 
relatively rare.
91 This might suggest that steroid-induced glaucoma is an entity mainly 
limited to younger age groups. However, Garbe et al. included only individuals 65 years 
and older in their study. The results of Garbe et al. seem to conflict with that of our 
cohort study. Possible explanations for this apparent discrepancy are power limitations in 
our study and selection bias in the study of Garbe et al. (Chapter 2). The age ranges 
were between 49 and 97 years in the study of Mitchell et al.
47 and 37.2 ± 14.3 years 
(mean ± standard deviation) in the study of Haeck et al.
48 
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Docetaxel and Paclitaxel 
 
Docetaxel and paclitaxel belong to the family of chemotherapeutic drugs called taxanes.
92 
They are used for the treatment of various neoplastic diseases including breast cancer.
93-
96 Taxane-induced glaucoma was first reported in 1999 by Fabre-Guillevin et al.
97 In their 
report, a 31-year-old woman with a history of breast carcinoma who was on docetaxel 
therapy and who also used corticosteroids as an adjunct therapy developed an elevated 
IOP of 44 mmHg (normal range 10-21 mmHg). Optic discs and visual fields were normal; 
the angle was wide open. Docetaxel was discontinued and a topical β-blocker was 
started, together yielding an IOP within the normal range. However, on follow-up 
treatment with paclitaxel and methylprednisone, the IOP increased again and cupping of 
the optic discs and visual field defects developed. The authors attributed these findings to 
taxane use despite the concurrent use of corticosteroids; they based this conclusion on 
the absence of visual complaints during earlier use of corticosteroids alone, before the 
use of taxane. De Giorgi et al.
98 reported a 56-year-old woman affected by breast cancer 
who developed bilateral visual field loss during treatment with paclitaxel. Unlike in the 
earlier case, this woman developed visual field loss without an increased IOP. This patient 
was part of a prospective study with 12 patients on paclitaxel therapy of whom two 
additional patients developed visual field loss. In all three cases, the visual field loss 
resolved within 6 months after the end of the therapy. The IOP was normal in all 12 
patients. De Giorgi et al. also suggested that the visual field loss might be due to 
neurotoxicity. 
 
The taxanes are recognized as evidenced-based essential components of therapy for 
metastatic breast cancer.
99 In 2008, 182.460 women were estimated to be diagnosed 
with breast cancer in the United States.
100 
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Despite the fact that paclitaxel and docetaxel are considered as fundamental drugs in the 
treatment of breast cancer, only one case of taxane-induced has been published thus 
far,
97 and in that case corticosteroids might have attributed to the OAG as well. All this 
questions the paradigm of taxane-induced OAG. 
 
 
Antihypertensive medications 
 
Antihypertensive medications including calcium channel antagonists (CCAs), β-blockers, 
diuretics and angiotensin converting enzyme (ACE) inhibitors are widely used drugs for 
the therapeutic management of hypertension.
101 Hypertension is an important risk factor 
for cardiovascular disease and cardiovascular disease have been implicated in the 
impaired vascular perfusion of the optic nerve head.
102 Because hypertension is generally 
treated with antihypertensive medications, it is difficult to attribute a possible increased 
risk of OAG to hypertension or its treatment. Several population-based studies have 
consistently reported an association between blood pressure and IOP .
103-107 Because 
blood pressure is positively associated with IOP, systemic hypertension may indirectly 
increases the risk of OAG. However, the evidence of an association between hypertension 
and OAG is not strong and most of the reports are inconsistent.
108-111 Antihypertensive 
medications have different mechanisms of actions. We hereby summarize the effects on 
OAG of the commonly used anti-hypertensive medications CCAs, β-blockers, diuretics 
and ACE inhibitors. 
 
Calcium channel antagonists 
 
The usage of CCAs in clinical medicine is dated back to the 1960’s.
112 CCAs mediate their 
actions through the inhibition of the influx of calcium ions in cells, which causes 
relaxation of the vascular smooth muscle cells, reduction of the vascular resistance and 124 
 
elevation of the regional blood flow in several organs including the eye.
113-117 Earlier 
studies have reported conflicting results about the effect of CCAs on IOP in both humans 
and rabbits.
118,119 In contrast, later studies have reported an IOP reduction in 
experimental animals and humans.
120-123 A beneficial effect of CCAs on the visual field in 
patients with normal tension glaucoma (NTG) has been reported.
124-127 In the study of 
Kitazawa et al., 25 consecutive patients with NTG received oral nifedipine 30 mg/day for 
six months.
124 The visual field was tested with standard automated perimetry prior to and 
monthly during the period of nifedipine administration. Six patients showed an 
improvement of the visual field as expressed by an increase in mean sensitivity (MS). In 
this study, there was no control group and they did not control for IOP; any differences in 
IOP between the groups. Koseki et al. studied 52 patients (average age 57.7 years) with 
NTG who were randomly assigned to receive oral brovincamine (20 mg three times daily) 
or to an untreated control group.
125 The two groups were followed prospectively for 2 
years with standard automated perimetry every 4 months. Changes in mean deviation 
(MD), corrected pattern standard deviation (CPSD), and total deviation (TD) at 74 test 
points were analyzed using regression analysis with a linear mixed model. They 
concluded that oral brovincamine seems to retard further visual field deterioration. Mean 
changes in MD (standard error) during the study period were -0.07 (0.20) and -0.78 
(0.18) dB/year in the brovincamine and control groups, respectively. In CPSD the mean 
changes (standard error) were 0.004 (0.016) and 0.032 (0.015) dB/year in the 
brovincamine and control group, respectively. The TD values were significantly 
deteriorating in six of 74 test points in the control group, whereas no points showed a 
significant trend in the brovincamine group (no P-vales provided). The analyses were not 
adjusted for IOP, but the differences were very small (average IOP 13.1 mmHg and 13.2 
mmHg in the brovincamine and control group, respectively). Sawada et al. followed a 
total of 28, age- and visual field-matched patients with NTG who were randomly allocated 
to either brovincamine or placebo for a minimum of 2.5 years.
126 Visual field 
examinations were carried out at least every 6 months. 125 
 
The mean (SD) follow-up periods were 39.1 (8.7) months and 37.9 (10.1) months in the 
brovincamine group and the placebo group, respectively. Stepwise discriminant analyses 
were performed to separate the patients who showed improvement in their visual fields 
from those who failed to improve in the brovincamine treated group. Brovincamine 
seemed to have a favourable effect on visual field in some patients with NTG as indicated 
by visual field improvements of six patients in the brovincamine treated group compared 
to none in the placebo group (no P-value provided). Sawada et al. did not correct for IOP. 
In another study, Koseki et al. examined the 3-year effect of oral nilvadipine on the visual 
field (as assessed with standard automated perimetry) and ocular circulation as assessed 
with the laser speckle method at 0,3,6, 12,18,24,30,and 36 months in NTG patients with 
a randomized placebo-controlled, double-masked, single centre trial.
127 Thirty-three 
patients were included (17 assigned to nilvadipine and 16 assigned to placebo); 13 in 
each group completed the study. Nilvadipine (2 mg twice daily) slightly slowed the visual 
field progression over 3 years in patients with NTG; the MD rate of progression was -0.01 
dB/year in the treated arm as compared to -0.27 dB/year in the controls (P=0.040). 
During the 3-year follow-up period, the average IOP was 12.6 mmHg in the nilvadipine 
group compared to 12.8 mmHg in the placebo group (P>0.1). In this study, Koseki et al. 
did not correct for IOP. However, this difference in IOP seems to be too small to explain 
their findings (the influence of IOP on the MD rate of progression is typically less than 0.1 
dB/year per mmHg).
128 Netland et al. compared 56 patients with either high tension 
glaucoma (HTG) or NTG who were currently taking CCAs to similar groups not taking 
such medication.
129 In this study, NTG patients taking CCAs demonstrated no evidence of 
progressive optic nerve damage after a mean follow-up period of 3.4 years whereas 
patients with HTG showed no marked difference in the progression of cases compared to 
controls. Like in the previously described studies, Netland et al. did not correct for IOP; 
any differences in IOP were not mentioned. In contrast to these clinical studies, two 
epidemiological studies suggested a harmful effect of CCAs on OAG. Langman et al. 
performed a large case-control study using a general practitioner database.
130 In this 126 
 
study, 27,080 glaucoma cases were matched with 27,080 controls for age and 
sex.Treatment with CCAs was a significant risk factor for OAG (OR 1.34; 95% CI 1.24-
1.44). Their result was consistent with the result of a prospective population-based 
cohort study by Müskens et al.
131 In this study, 3842 participants were followed for 6.5 
years. Participants using CCAs had an 1.8 fold (95% CI 1.04-3.2) higher risk of 
developing OAG during follow-up. Unlike the analysis by Langman et al, Müskens et al. 
adjusted for the IOP, suggesting that the harmful effect of CCAs on OAG is IOP 
independent. Müskens et al. argued that the difference between their study and the 
aforementioned studies may be attributed to patient selection. The epidemiological 
studies do not rule out that a small, selective group of NTG patients might benefit from 
CCAs. It might also be the case that age plays a role in the observed differences. In 
Müskens et al, the mean age of the cases and controls was 71.2 and 74.2 years, 
respectively. In the First study of Koseki, the average age of the included 52 patients was 
57.7 years and in his second study mentioned that patients with OAG were younger than 
65 years. Apparently, the relationship between CCAs and OAG is not yet completely 
solved. 
 
Beta blockers 
 
Beta-adrenegic blocking agents otherwise known as β-blockers are generally classified as 
selective or non-selective based on their affinity to block either β1  or  β2 adrenergic 
receptors, or both.
132 The therapeutic ocular hypotensive effect of β-blockers in patients 
was first published in a paper by Phillips et al. in 1967, using propranolol.
133 The 
introduction of topical timolol, a non-selective β-blocker in the late 1970s has paved the 
way for β-blockers use as a therapy for glaucoma.
134,135 The mechanism of action is 
mediated through the inhibition of aqueous humour secretion and thus lowering 
IOP.
136,137 
 127 
 
In contrast to the indisputable beneficial effects of topical β-blockers on OAG, the effects 
of systemic β-blockers are less clear. Unlike in the era of CCAs, clinical trials with 
systemic β-blockers seem not to exist. Three epidemiological studies addressed the role 
of systemic β-blockers in OAG. 
 
In a prospective population-based cohort study, Müskens et al.
131 reported that the use of 
β-blockers was associated with a non-significant risk reduction of OAG (OR 0.6; 95% CI 
0.3-1.02). Their result was consistent with the abovementioned study by Langman et al. 
who reported a reduced risk of glaucoma in users of β-blockers (OR 0.77; 95% CI 0.73-
0.83).
130 In addition, Owen et al. also reported that the systemic use of β-blockers was 
associated with a lower risk of glaucoma (OR 0.87; 95% CI 0.80-0.94).
138 Their study 
was a case-control study performed within a primary care database. According to the 
authors, a possible explanation for this finding may be attributed to more complex 
pharmacological properties, including neuroprotective effects, ocular penetration and 
influences on the haemodynamics including effects on ocular blood flow and perfusion 
pressure.
138 Hence, systemic β-blockers seem to slow down the development of OAG. 
 
Diuretics 
 
Diuretics have been the first line of treatment of hypertension for decades.
139 Their usage 
in ophthalmology can be traced back to Richard Middlemore who, in 1835, treated acute 
glaucoma by a mercury diuretic in the form of a blue pill.
140 Diuretics mediate their 
mechanism of action by diminishing sodium reabsorption at different sites in the nephron 
thereby increasing urinary sodium and water losses.
141,142 Several studies reported about 
the association between the use of diuretics and OAG. In a randomized, double masked, 
controlled clinical trial, Miglior et al.
143 reported that the use of systemic diuretics was 
associated with an increased risk of the development of OAG (Hazard ratio [HR] 2.41; 
95% CI 1.12-5.19) whereas the presence of systemic hypertension was not. The authors 128 
 
argued that the significance of diuretics may be explained by chance alone, by a 
idiopathic detrimental effects of diuretics on the retinal ganglion cells or by a possible 
decrease of ocular perfusion pressure induced by its pharmacological reduction of 
systemic blood pressure. In addition, they observed that diuretics were more often used 
in combination with other antihypertensive medications, especially among those who 
developed OAG. However, because they did not measure blood pressure in their study, it 
is difficult to unravel the effects of blood pressure, the use of other antihypertensive 
medications or, for example, more complex interactions between both.
143 Langman et al. 
reported a small but significant risk of the use of diuretics in current users (OR 1.08; 
95% CI 1.03-1.14) and ever users (OR 1.13; 95% CI 1.08-1.18).
130 Also Owen et al 
reported a small increased risk in their case-control study performed within a primary 
care database (OR 1.13; 95% CI 1.04–1.23). In contrast, Müskens, in their prospective 
population-based cohort study did not find any significant effect for either low-ceiling (OR 
0.8; 95% CI 0.4-1.4) or high-ceiling (OR 0.8; 95% CI 0.4-1.8) diuretics.
131 A small 
harmful effect of diuretics could possibly be explained by residual confounding as 
diuretics tend to be prescribed to elderly patients with hypertension,
144 and linear 
adjustment for age (the most common approach) might not completely address the 
effect of age on the prevalence or incidence of OAG.
40,145 
 
Angiotensin converting enzyme inhibitors 
 
Apart from the therapeutic management of hypertension, ACE inhibitors have also been 
shown to lower IOP in patients with ocular hypertension or primary OAG.
146,147 Although 
the precise mechanism is not yet understood, the rennin enzymatic system (RAS), an 
enzymatic cascade that generate a wide range of angiotensin peptides with varying 
biological actions are thought to be involved in the regulation of aqueous outflow and IOP 
reduction.
148,149 The major component of RAS has been documented in the human 
eye.
150,151 129 
 
Genetic studies thus far provided inconclusive evidence about the effects of ACE 
inhibitors on OAG. Bunce et al. reported no consistent evidence between ACE genotype 
and ocular signs of POAG but found evidence of an association between ACE genotype 
and optic disc size.
152 Hirooka et al. reported that ACE inhibitors might have a favourable 
effect on the visual field in patients with normal tension glaucoma (NTG).
153 Their finding 
was based on a retrospective observational case series that reviewed 38 patients with 
NTG. Control subjects (n=13) had no previous history of hypertension and the NTG 
patients with hypertension were divided into two groups; those receiving ACE inhibitors 
(n=12) and those receiving other antihypertensive medications (n=13). The mean follow-
up (standard error of measurement [SEM]) was 49.8 (3) months for the control group, 
42.4 (2.2) months for the ACE-inhibitor group and 46.8 (2.8) months for those receiving 
other antihypertensive medications. The mean (SEM) MD change per year was 0.48 
(0.19) dB in the ACE inhibitor-treated group, -0.38 (0.23) dB in control subjects and -
0.50 (0.39) dB in the anti-hypertensive drug-treated group (P=0.04). There was no 
difference between the maximum and minimum IOP measured for the control group, 
ACE-inhibitor group and those receiving other antihypertensive medications (P=0.24 and 
P=0.62, respectively). Langman et al in their large case-control study reported that the 
use of ACE inhibitors was associated with an increased risk of glaucoma (OR 1.34; 95% 
CI 1.24-1.44).
130 They suggested that the observed association might be attributed to 
the failure of ACE inhibitors to protect against a commonly associated disease rather than 
an increased risk caused by treatment, a suggestion based on the fact that the ORs were 
virtually identical in known current users of ACE inhibitors (OR 1.34; 95% CI 1.24-1.44) 
and ever uses of the drug (OR 1.30; 95% CI 1.21-1.38). Müskens et al. reported no 
significant effect of ACE inhibitors on OAG (OR 0.9; 95% CI 0.5-1.7).
131 Apparently, the 
relationship between ACE inhibitors and OAG is not yet completely solved. 
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Antithrombotics 
 
Antithrombotic drugs are frequently used prophylaxis against impaired blood flow.
154 
Although the exact pathogenesis of OAG is yet to be unravelled, impaired blood flow has 
been postulated to be involved in the retinal ganglion cell death as seen in OAG.
155 We 
investigated the association between the use of these drugs and the development of OAG 
in 3939 participants aged 55 years and older from the prospective population-based 
Rotterdam study.
156 The use of anticoagulants and platelet aggregation inhibitors was 
monitored continuously during follow-up. During a mean follow-up of 9.8 years, 108 
(2.7%) of 3939 eligible participants developed OAG. The hazard ratio (HR) for 
anticoagulant use was 0.95 (95% CI 0.58 to 1.54; P=0.818) and for platelet aggregation 
inhibitors 0.80 (0.53 to 1.20;  P=0.281). There was no significant trend towards a 
reduced risk of incident OAG with prolonged anticoagulant use (HR 0.80, 95% CI 0.44-
1.44, P=0.45 and HR 0.76, 95% CI 0.41-1.39, P=0.37) and platelet aggregation 
inhibitors use (HR 1.17, 95% CI 0.57-2.43, P=0.67 and HR 0.81, 95% CI 0.51-1.28, 
P=0.37) for usage during two years or less and during more than two years, 
respectively.
156 Our study suggests that the use of anticoagulants and platelet 
aggregation inhibitors seems not to be associated with OAG. Thus far, apparently no 
other studies addressed this relationship. 
 
 
Carbonic Anhydrase Inhibitors 
 
The usage of carbonic anhydrase inhibitors (CAIs) in ophthalmology can be traced back 
to Becker,
157 who used acetazolamide in the management of glaucoma, in 1954. Since 
then, CAIs have been used widely for controlling IOP in glaucoma.
158 The mechanism of 
action of CAIs is to block carbonic anhydrase, which catalyses the conversion of carbon 
dioxide to bicarbonate.
159,160 The inhibition of carbonic anhydrase results in the decrease 131 
 
of aqueous humour production in the ciliary processes and thus lowers the IOP.
161 Until 
recently, CAIs were only available for oral use and – due to numerous side effects - its 
use was essentially limited to the treatment of acute high intraocular pressures.
162-165 
Nowadays, topical CAIs are available with fewer systemic side effects.
166,167 The IOP 
lowering effect of two commonly prescribed CAI have been documented in a meta-
analysis of randomized clinical trials.
168 In this meta-analysis, dorzolamide and 
brinzolamide had a mean IOP lowering effect of -4.5 to -5.9 mmHg and -4.4 to -4.5 
mmHg, respectively. As these pressure-lowering effects are somewhat smaller than that 
of oral CAIs, the oral CAIs remain very useful in special cases.
169 
 
Apart from their IOP lowering effect, CAIs have also been reported to improve the 
regulation of ocular perfusion, although evidence is limited.
170 Flammer and Drance 
reported a case of a 28-year-old woman with early glaucoma. Automatic perimetry 
showed reproducible improvement of the differential threshold responses in the visual 
field following 12 hours of acetazolamide therapy.
171 On the first occasion, the patient 
took three 250 mg tablets of acetazolamide over a 12-hour period and reported 
subjective improvement. Five months later, the patient again received three 250-mg 
tablets of acetazolamide over a 12-hour period, then underwent perimetry again and also 
reported improvement in her vision. Altogether, five visual field tests were performed. 
 
 
Cannabinoids 
 
Marijuana is the crude drug derived from dried leaves and flowering parts of the hemp 
plant Cannabis sativa.
172,173 It has a long history of use in medicine and recreation and 
contains more than sixty group of compounds known as cannabinoids with 
9-
tetrahydrocannabinol (THC) being the most pharmacologically active component.
174-176 
Hepler and Frank were the first to report a decrease in IOP after smoking marihuana. 132 
 
In 1971, they observed that smoking marijuana could lower IOP by up to 45% in normal 
subjects.
177 Since then, several other studies have reported ocular hypotensive effects of 
different cannabinoids.
178-182 The mechanism of action by which cannabinoids lower the 
IOP is not fully understood.
183-185 Recent studies have also reported neuroprotective, anti-
oxidative and vasorelaxant properties of cannabinoids.
186-191 Hence, cannabinoids might 
modify the risk of glaucoma – apart from via their IOP-lowering effect - by (1) inhibiting 
neuronal cell death, (2) scavenging toxic reactive oxygen species and (3) increasing the 
ocular blood flow. However, the clinical usefulness of cannabinoids has been limited by 
the development of tolerance and systemic side effects.
192 
 
 
Ginkgo biloba extract 
 
Ginko biloba extract (GBE) is a Chinese traditional medicine obtained from the leaves of 
the Ginko biloba tree. Reports from early manuscripts shows that GBE has been used 
since 3000 BC.
193,194 They have been reported to ameliorate numerous disorders 
including peripheral vascular disease, cerebral insufficiency, dementia and Alzheimer.
195-
198 
 
GBE has been reported to increase ocular blood flow but not IOP in a phase 1 cross-over 
trial of GBE with placebo control in 11 healthy volunteers (8 women, 3 men) aged 34 
(standard deviation 3) years.
199 In this study, subjects were administered 40 mg GBE or 
placebo three times daily for 2 days. Color doppler imaging was used to measure ocular 
blood flow before and after treatment. GBE significantly increased end-diastolic velocity 
in the ophthalmic artery (baseline versus GBE-treatment [mean with standard deviation 
between brackets]: 6.5 (0.5) versus 7.7 (0.5) cm/s; P=0.023) with no changes seen in 
placebo (baseline versus placebo: 7.2 (0.6) versus 7.1 (0.5) cm/s; P=0.892). GBE did 
not show any significant effect on IOP (baseline versus GBE-treatment: 13.5 (0.9) versus 133 
 
14.0 (1.0) mmHg; P=0.716) with no changes seen in placebo (baseline versus placebo: 
14.6 (0.8) versus 14.0 (1.0) mmHg; P=0.290).
199 In another study, Quaranta et al. 
evaluated the effect of GBE on pre-existing visual field damage in patients with NTG. In 
this prospective, randomized, placebo-controlled, double-masked cross-over trial, GBE 
significantly improved visual field damage in 27 patients with normal tension glaucoma 
without altering the IOP.
200 Patients were administered 40 mg GBE, three times daily for 
4 weeks followed by a wash-out period of 8 weeks, then 4 weeks of placebo. Other 
patients were first administered the placebo and then GBE. Visual field tests were 
performed at baseline and at the end of each phase of the study using Humphrey field 
analyser [HFA]. After GBE treatment, a significant improvement in visual fields indices 
was recorded; MD at baseline versus MD after GBE treatment was -11.4 (3.3) dB versus 
-8.8 (2.6) dB (p=0.0001). The improvement was not maintained after 8 weeks of 
washout. No significant changes were found in IOP. An explanation for this observation as 
suggested by the authors was the ability of GBE to increase cerebral blood flow and thus 
improving ocular blood flow and invariably improving retinal sensitivity as well as 
concentration and alertness.
199 Other properties of GBE reported in the literature include 
neuroprotection, platelet activating factor inhibitory activity, nitric oxide inhibition, 
antioxidation, inhibition of apoptosis and excitotoxicity.
201-206 
 
 
Cholesterol-lowering drugs 
 
The quest to discover microbial metabolites that would inhibit 3-hydroxyl-3-
methylglutaryl coenzyme A (HMG-CoA) reductase lead to the discovery of a potent 
reductase inhibitor mevastatin in the 1970’s.
207 Since then, other mevastatin analogues 
have been developed in the 1980s and 1990s.
208,209 Nowadays, statins are recognized as 
potent cholesterol-lowering drugs.
210 Several studies have reported various beneficial 
effects of statins on stroke, Alzheimer’s disease, and a variety of eye diseases such as 134 
 
age related maculopathy, cataract and diabetic retinopathy.
211-218 A few studies have 
explored the association between cholesterol-lowering drugs and OAG.
219-221 
 
McGwin et al. performed a large nested case-control study using an administrative 
clinical database. Cases were all male patients aged 50 years and older with a new 
diagnosis of glaucoma. Ten controls subjects were matched to each case according to age 
within a year. In this study, 667 cases were matched with 6667 controls and prescription 
files were assessed for statin use as well as additional medications to lower cholesterol 
levels. Long-term use of statin was associated with a lower risk of OAG (OR 0.60; 95% 
CI 0.39-0.92). Non-statin cholesterol-lowering agents were also associated with a 
reduced risk of having OAG (OR 0.59; 95% CI 0.37-0.97).
219 In contrast, Owen et al. 
found no evidence for a protective effect of statins (OR 0.97; 95% CI 0.88-1.06) in 
another case control study nested within a computerized primary care database of 177 
general practices across the UK. In this study, 8778 cases diagnosed and/or treated for 
glaucoma were matched with 8778 glaucoma free controls for age, gender and 
practice.
138 
 
Recently, we reported that the use of statins was associated with a reduced risk of OAG 
(Hazard ratio [HR] 0.56; 95%CI 0.32 to 0.97), in a prospective population-based cohort 
study.
17 However, unlike McGwin et al, the use of non-statin cholesterol-lowering drugs 
(NSCLDs) was not associated with a reduced risk of OAG (HR 1.82; 0.71-4.66). The lack 
of association between NSCLDs and OAG might be attributed to the low number of users 
of NSCLDS in our study.
17 Furthermore, De Castro et al. reported that the use of statins 
was associated with a slower progression of glaucomatous optic nerve atrophy.
221 To 
determine the effect of statins on the rate of progression of optic nerve parameters in 
OAG, as defined by confocal scanning laser ophthalmoscopy (CSLO), they conducted a 
retrospective chart review. Their study included 149 eyes from 76 patients considered 
suspect for glaucoma based on cup-to-disc ratio >0.5, but with normal IOP and visual 135 
 
fields. Cases included glaucoma suspects who took statin drugs for more than 23 months 
and the control group were glaucoma suspects who never used statins. All patients 
underwent optic nerve head imaging using the Heidelberg Retinal Tomograph [HRT] and 
visual field testing with HFA. Comparing controls with the statin group there were 
significant differences in the progression of multiple CSLO parameters, including rim 
volume, retinal nerve fibre layer cross-sectional area, and mean global retinal nerve fibre 
layer thickness, with adjustment for age, gender, race, IOP, CCT, refractive error and 
multiple systemic morbidities. 
 
The mechanism by which cholesterol-lowering drugs might reduce the risk of OAG is yet 
to be elucidated. McGwin et al. suggested that the mechanism might be IOP mediated 
whereas Marcus et al. attributed the mechanism to anti-inflammatory and neuro-
protective properties of statins on neuronal cells – per exclusion - because the observed 
protective effect was IOP-independent.
222-226 Likewise, De Castro et al. corrected for IOP 
in their model and attributed their findings to optic nerve head changes suggestive of a 
neuroprotective effect of statins against glaucoma progression. 
 
 
Estrogens 
 
Estrogens, the female sex hormone, are steroid hormones that play an important role in 
the growth and development of various tissues throughout the body.
227 Their presence 
have also been reported in various ocular tissues.
228 Estrogens exert their effect by 
binding to two estrogen receptors.
229 Various studies have reported a higher incidence 
and prevalence of OAG in men.
230-232 This observation was also confirmed in a meta-
analysis in which men were 1.37 (95% credible interval 1.22 to 1.53) times more likely 
than women to have OAG.
233 Earlier studies have reported higher IOP among 
postmenopausal woman than in premenopausal women and in men of similar age.
234-236 136 
 
 
In addition, a study has reported an increased risk of OAG in early menopausal women
 
and female sex has been reported to be a risk factor in normal tension glaucoma.
237,238 
Except for the latter study, these observations might suggest a protective role of 
estrogen in the era of OAG. Studies performed in women on hormone replacement 
therapy have reported significant decreases in IOP and significant increases in tear 
break-up time and schirmer test.
239-242 The decrease of IOP as a result of the systemic 
hormone replacement has been attributed to estrogen.
243 Furthermore, estrogen has 
been applied as topical drop with promising result in patients with keratoconjuctivitis 
sicca.
244 Ozcura et al. therefore proposed that topical estrogen drops may be a new 
alternative in the treatment of glaucoma.
245 This, however, has been questioned by 
others.
246 
 
 
Conclusion 
 
Several systemic drugs have been related to IOP and/or OAG but the reported effects are 
unequivocal for a limited number of these drugs only. Table 2 summarizes the findings 
from this review. The role of steroids and CAI is already part of the clinician's 
armamentarium. There seems to be no basis for a universal avoidance or 
recommendation of the use of any class of antihypertensive drugs if needed for an 
adequate regulation of the blood pressure. However, clinicians should be aware of 
possible effects on OAG in individual patients. Of the other systemic drugs listed in Table 
2, the statins seem to be closest to a potential clinical application in the management of 
OAG - given our current state of knowledge that the use of supplementary treatment that 
protects retinal ganglion cell death independent of an IOP lowering is warranted. 137 
 
Table 1 Age distribution of case studies and case series reporting an association between 
steroid use and open-angle glaucoma 
          
Sources 
 
Age 
(years)
Types ofsteroid 
used 
Estimated 
duration 
of use 
Other risk 
factors 
Francois J, 1954
50  35 Ophthalmic  3 years  NA 
Goldmann H, 1962
51  31 
43 
57 
9.5 
34 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Months 
Years 
Months 
Years 
2 years 
Myopia 
DM 
- 
- 
FH, myopia 
Bernstein HN, 1963
52  25 Oral,  Ophthalmic  1 year  FH 
Armaly MF, 1963
53,54  32 
42 
44 
Ophthalmic 
Ophthalmic 
Ophthalmic 
4 weeks 
3 months 
Months 
FH 
- 
- 
Mills DW, 1965
55  17 Ophthalmic  Years  NA 
Long WF, 1977
56  20 Oral  Days  Myopia 
Michaeli-Cohen 
A,1998
57 
35 
45 
Ointment 
Ointment 
Years 
Years 
FH, myopia 
- 
Garrott HM, 2004
58  40 
71 
55 
Ointment 
Ointment 
Ointment 
- 
Weeks 
6-9 months 
- 
FH 
FH 
van Boxtel LA, 2005
59  20 
28 
32 
Ophthalmic, Ointment 
Ophthalmic, Ointment 
Ophthalmic, Ointment 
Years 
Years 
Years 
NA 
NA 
NA 
Eisenlohr JE, 1983
60  33 Ointment  4  years  - 
Ross JJ, 2004
61  42 Ointment  2 years  NA 
Sahni D, 2004
62  29 Ointment  Years  FH 
Zugerman C, 1977
63  30 Ointment  Years  - 
Nielson NV, 1978
64  68 
80 
Ointment 
Ointment 
2 years 
3 years 
DM 
NA 
Park JJ, 2002
65  6.5* Ophthalmic  >6 weeks  Myopia 
Butcher JM, 1994
66  47 Ophthalmic  3 years  - 
McLean CJ, 1995
67  30 Ointment  5 Years  - 
Cubey RB, 1976
68  22 Ointment  7 years  - 
Vie R, 1980
69  29 Ointment  Years  - 
Aggerwal RK et al.
1993
70 
24 
23 
25 
Ointment 
Ointment 
Ointment 
>2 years 
>11 years 
>3 years 
NA 
NA 
NA 
Dreyer EB, 1993
71  57 inhaled  6 months  - 
Woods AC, 1950
72  17 Ophthalmic  10 days  - 
Opatowsky I, 1995
73 71 
61 
Nasal 
Nasal 
5 months 
Months 
DM 
Brubaker R, 1975
74  18 Ointment  Years  - 
Covell LL, 1958
75  58 
59 
65 
Oral 
Oral 
Oral 
>1 year 
Years 
Years 
Arthritis 
FH, Arthritis 
HT, Arthritis 
Stern JJ, 1953
76 59  Oral  Days  - 
thoe Schwartzenberg
GW 1999
77 
26 
22 
Ointment 
Ointment 
7 years 
>9 years 
Myopia 
JG 
Hutcheson KA, 2007
78  3+ Ophthalmic  1 week  - 138 
 
Sasaki R, 2003
79  29 Ophthalmic  6 months  - 
Wax M, 1998
80  17 Ophthalmic  4 months  - 
Perkins ES, 1965
81  31 oral  Months  - 
Tham cc, 2004
82  9 Oral  Weeks  - 
Al-Shahwan S, 2006
83 9*  0ral  Months  - 
Phillips RP et al. 1990
84  37 
16 
Ophthalmic 
Ophthalmic 
Months 
> 1 year 
NA 
NA 
Burde RM, 1970
85  17 
20 
Ophthalmic 
Ophthalmic 
Years 
Years 
FH 
Myopia 
Hales RH, 1973
86  19 
16 
Ophthalmic, Ointment 
Ointment 
3 years 
3 years 
NA 
NA 
Baratz KH et al. 1999
87  31 
56 
Ointment 
Ophthalmic 
4 years 
6 months 
Myopia 
History of 
glaucoma 
Al-Samarrai AR, 1993
88  47 
43 
56 
Ointment 
Ointment 
Ointment 
  NA 
NA 
NA 
Kim JH, 1969
89 
 
30 
32 
35 
23 
38 
40 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
9 years 
1 year 
3 years 
1 year 
1 year 
10years 
NA 
NA 
NA 
NA 
NA 
NA 
Spaeth GL, 1977
90 
 
15 
43 
16 
45 
31 
43 
Ointment, Ophthalmic 
Ophthalmic 
Ophthalmic 
Ophthalmic 
Ointment, Ophthalmi
Ophthalmic 
5 years 
3 years 
1 year 
Months 
2 Weeks 
5 weeks 
NA 
NA 
NA 
NA 
NA 
NA 
 
Abbreviations: NA=not available; - =unknown; FH=family history of glaucoma; 
JG=Juvenile glaucoma; DM=diabetes mellitus; HT=Hypertension; *=Age in 
months;+=Age in weeks. 139 
 
Table 2 Summary 
Medications Effect  on 
IOP 
Effect on OAG  Presumed mechanisms  Additional remarks 
Corticosteroids  Increase  Harmful  Effect on IOP caused by 
changes in the trabecular 
meshwork; effect on 
OAG through effect on 
IOP 
Steroid responders at 
higher risk of 
developing OAG 
Docetaxel & 
Paclitaxel 
Harmful/ 
Conflicting 
Harmful/ 
conflicting 
Unknown  Based on a single case 
study 
Calcium 
antagonists 
Conflicting 
(possible 
decrease) 
Conflicting  Elevation of ocular blood 
flow 
Contradicting results 
from human and animal 
studies 
(IOP); 
contradicting results 
from clinical studies in 
NTG patients and 
epidemiological studies 
(OAG) 
Beta-blockers  Decrease  Protective  Inhibition of aqueous 
humor secretion 
Evidence form three 
epidemiology studies; 
no clinical studies 
available 
Diuretics None  Conflicting 
(possible small 
harmful effect) 
Unknown  
ACE-inhibitors  Decrease  No clear effect  Regulation of aqueous 
outflow via RAS 
 
Antithrombotics None  None  NA  Evidence from a single 
population- based study 
CAI  Decrease  No clear effect  Decrease  in  aqueous 
production 
by inhibition of carbonic 
anhydrase 
Side effects have limited 
usage of systemic CAI 
Cannabinoids Decrease  Unknown  (no 
studies with a 
sufficiently long 
follow-up 
available) 
Unknown  Therapeutic use limited 
by the development of 
tolerance and systemic 
side effects 
GBE None  None  (only  short-
term improvement 
of visual field) 
Elevation of ocular blood 
flow 
Short-term effect 
Cholesterol-
lowering drugs 
None Protective  Neuroprotection   
Estrogens  Decrease  Protective  Unknown  Effect on OAG only form 
indirect evidence 
(male/female 
differences and effects 
of menopause) 
 
Abbreviations: IOP=Intraocular pressure; OAG=Open-angle glaucoma; NTG=Normal 
tension glaucoma; ACE=Angiotensin converting enzyme; NA= Not available; 
CAI=Carbonic Anhydrase Inhibitors; GBE=Ginkgo biloba extract. 140 
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Summary 
Glaucoma is a heterogeneous group of disease characterized by optic neuropathy and 
progressive visual field defects. An elevated intraocular pressure (IOP) is regarded as the 
major risk factor and the therapeutic management of OAG is currently targeted 
exclusively towards the lowering of IOP. The prevalence of glaucoma is expected to 
increase sharply in the coming decades with the current pace of population ageing. 
According to the World health organization, glaucoma accounts for the loss of nearly 6 
million disability-adjusted life years (DALYs) per year. Because OAG is the most common 
form of glaucoma, the economic and social burden of this disease is also expected to 
increase. In order to ameliorate the economic and social burden of OAG a better 
understanding of the risk factors is expedient. On the basis of previously proposed risk 
factors and the current state of knowledge, we sought to evaluate the effect of some 
systemic medications and other risk factors of OAG. Chapters one, two and three are 
based on the prospective population-based Rotterdam Study initiated in 1990-1993 in 
7,983 individuals aged 55 years and older living in the Ommoord district of Rotterdam, 
the Netherlands. For this study, data from a subset of 3939 participants who did not have 
OAG at baseline and who completed at least one follow-up examination was used.	We 
had detailed information on prescriptions of all investigated medications from the local 
pharmacy records from January 1, 1991, and during complete follow-up. 
 
Previous studies have reported beneficial effects of statins on a variety of eye diseases 
such as age-related maculopathy, cataract and diabetic retinopathy. However, there is 
conflicting evidence regarding the effects of statins and non-statin cholesterol-lowering 
drugs (NSCLDs) on OAG. In Chapter 1 we showed that long-term use of statins was 
associated with a reduced risk of OAG and the observed effect was IOP independent. Our 
observation corroborates the results of earlier studies in favor of a beneficial effect of 
statin on OAG. However, we found no significant benefit effects of NSCLDs on OAG. 
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Evidence mainly from case reports and case series has suggested that corticosteroids can 
cause a substantial rise in IOP and thus induce OAG. However, it is largely unknown if 
this adverse effect of corticosteroids is limited to a few susceptible individuals or 
contributes to the burden of OAG in the population. Chapter 2 describes the associations 
between the use of corticosteroids and incident OAG in the Rotterdam Study. We found 
that the use of any class of corticosteroids seems not to be associated with the incidence 
of OAG at the population level in the elderly. The majority of the previously published 
steroid-induced glaucoma cases were amply younger than the youngest age of our study 
cohort. 
 
Although the exact pathogenesis of OAG is yet to be unravelled, impaired blood flow has 
been postulated to be involved in the retinal ganglion cell death as seen in OAG. 
Antithrombotic drugs such as anticoagulants and platelet aggregation inhibitors are 
frequently used prophylaxis against impaired blood flow. In Chapter 3 we investigated 
the association between the use of antithrombotic drugs and the development of OAG in 
the Rotterdam Study. This is the first study to investigate the association between the 
use of anticoagulants and OAG; we found no significant beneficial effect of the use of 
antithrombotic drugs on the risk of OAG. The major limitation of this study is the small 
number of glaucoma cases and the small number of users of some classes of 
antithrombotic drugs which prohibits us from carrying out secondary analysis. 
 
There is mounting evidence in the literature about risk factors for the progression of 
OAG. IOP has been established as a risk factor the progression of OAG. Despite several 
well-executed clinical trials,
  other risk factors remain controversial. In Chapter 4 we 
used several statistical approaches to identify the risk factors associated with visual field 
progression in OAG and determined the influence of these statistical approaches in the 
Groningen Longitudinal Glaucoma Study (GLGS), a prospective cohort study in a clinical 
setting. 157 
 
We included 221 eyes of 221 patients from GLGS. On average 7.2 reliable fields were 
available after a mean follow-up of 5.4 years and 89 eyes progressed. We found that 
IOP, disease stage and age were robust independent risk factors for visual field 
progression in OAG. 
 
Chapter 5 addresses an important clinical question: is myopia a risk factor of OAG? 
Myopia has long been identified as a risk factor for OAG. However, there is conflicting 
evidence concerning the range of refractive error important for OAG. While some studies 
have reported an association with any myopia, others have found the relationship only in 
individuals with high myopia. In order to reconcile this controversy we carried out a 
systematic review and meta-analysis. Thirteen studies involving 48,161 individuals met 
the inclusion criteria; data from 11 population-based cross-sectional studies were 
included in the main analyses. The pooled relative risk of the association between myopia 
and glaucoma based on 11 risk estimates was 1.92 (95% confidence interval 1.54 to 
2.38). Based on seven risk estimates, the pooled relative risks of the associations 
between low myopia (myopia up to -3 dioptres) and glaucoma and high myopia (-3 
dioptres and more myopic) and glaucoma were 1.65 (1.26 to 2.17) and 2.46 (1.93 to 
3.15), respectively. After omitting studies that contributed significantly to heterogeneity, 
the pooled relative risk was 1.88 (1.60 to 2.20) for any myopia and glaucoma and 1.77 
(1.41 to 2.23) for low myopia and glaucoma. Therefore, we could conclude that 
individuals with myopia have an increased risk of developing OAG. 
 
In Chapter 6 the current state of knowledge of systemic medications and OAG is 
reviewed. Medications administered systemically within the body can cause a substantial 
rise in IOP and thus induce OAG. Corticosteroids are the most well-known and 
extensively studied medications with such property. Anti-neoplastic agents such as 
docetaxel and paclitaxel and anti-hypertensive medication such as calcium channel 
antagonists have also been reported with such effects. 158 
 
In contrast, medications like carbonic anhydrase inhibitors,
 beta blockers,
 cannabinoids,
 
ginkgo biloba extract and cholesterol-lowering drugs have been reported to diminish the 
risk and thus seem to have protective effect independent of IOP probably mediated via 
neuroprotective property. This presents an opportunity for clinical applicable treatment of 
OAG other than by means of lowering IOP but additional evidence is deemed appropriate. 
In addition, many studies have suggested a protective role of estrogens on the risk of 
OAG but more research are need to confirm this effect and in our study population, the 
use of anticoagulants and platelet aggregation inhibitors seems not to be associated with 
glaucoma. 159 
 
Samenvatting 
Glaucoom is een heterogene groep van aandoeningen van de oogzenuw die gekenmerkt 
wordt door een versnelde beschadiging van de oogzenuw gevolgd door 
gezichtsveldverlies. Een hoge oogdruk is de belangrijkste risicofactor en tevens het 
belangrijkste aangrijpingspunt voor de behandeling van glaucoom. Wereldwijd is 
glaucoom de op één na belangrijkste oorzaak van blindheid. 
 
De vergrijzing van de wereldbevolking zal de prevalentie van glaucoom doen toenemen in 
de komende decennia. Volgens de Wereldgezondheidsorganisatie is glaucoom 
verantwoordelijk voor het verlies van bijna 6 miljoen “disability-adjusted life years” 
(DALY's) per jaar. In de westerse wereld is openkamerhoekglaucoom (OKG) de meest 
voorkomende vorm van glaucoom. Te verwachten is dat de economische en sociale lasten 
van deze ziekte toenemen. Met het oog op een verbetering van de economische en 
sociale lasten van OKG is een beter begrip van de risicofactoren nuttig. Het onderzoek 
beschreven in dit proefschrift beschrijft de invloed van een aantal veelgebruikte 
medicamenten en andere risico factoren op OKG. De hoofdstukken 1, 2 en 3 zijn 
gebaseerd op het in 1990-1993 gestarte prospectieve Erasmus Rotterdam Gezondheid 
Onderzoek (ERGO/ Rotterdam study) onder 7983 mannen en vrouwen van 55 jaar en 
ouder, woonachtig in de Rotterdamse wijk Ommoord. Voor deze studies werden de 
gegevens van 3939 personen zonder glaucomateus gezichtsveldverlies bij aanvang van 
de studie gebruikt. We hadden gedetailleerde geautomatiseerde informatie tot onze 
beschikking over voorschriften van alle onderzochte medicijnen van de plaatselijke 
apotheekadministratie vanaf 1 januari 1991, en tijdens de volledige follow-up. 
 
Eerdere studies hebben gunstige effecten van statines op verschillende oogziekten zoals 
leeftijdsgebonden maculopathie, cataract en diabetische retinopathie gerapporteerd. 
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Echter, er is tegenstrijdig bewijs over de effecten van statines en overige 
cholesterolverlagende medicijnen (NSCLDs) op OKG. In Hoofdstuk 1 toonden we aan dat 
langdurig gebruik van statines was geassocieerd met een verlaagd risico van OKG en het 
waargenomen effect was onafhankelijk van de intraoculaire druk (oogdruk). Onze 
waarneming bevestigt de resultaten van eerdere studies in het voordeel van een gunstig 
effect van statines op OKG. We vonden geen significante effecten van de overige 
cholesterolverlagende medicijnen op OKG. 
 
Case reports en case series hebben laten zien dat corticosteroïden een aanzienlijke 
stijging van de oogdruk kunnen veroorzaken en dus steroïdgeïnduceerd glaucoom. Het is 
echter grotendeels onbekend of dit nadelige effect van corticosteroïden beperkt is tot een 
paar voor steroiden gevoelige personen of bijdraagt aan de last van OKG op populatie 
niveau. Hoofdstuk 2 beschrijft de associaties tussen het gebruik van corticosteroïden en 
de incidentie van OKG in de ERGO studie. We vonden voor geen van de 
toedieningsvormen van corticosteroïden dat het gebruik geassocieerd lijkt te zijn met de 
incidentie van OKG op populatieniveau bij ouderen. De meerderheid van de eerder 
gepubliceerde steroïdgeïnduceerde glaucoomgevallen waren ruimschoots jonger dan de 
jongste leeftijdsgroep van ons studiecohort. 
 
Hoewel de exacte pathogenese van OKG nog niet ontrafeld is, heeft men verondersteld 
dat een verminderde bloedtoevoer van invloed is op de celdood van de retinale ganglion 
zoals die te zien is in OKG. Antitrombotische geneesmiddelen zoals 
trombocytenaggregatieremmers  en anticoagulantia worden vaak gebruikt als profylaxe 
tegen een verminderde doorbloeding. In hoofdstuk 3 onderzochten we de associatie 
tussen het gebruik van antitrombotica en de ontwikkeling van OKG in de ERGO Studie. In 
deze studie, de eerste die naar het verband tussen anticoalgulantia en OKG keek, vonden 
we geen significant gunstig effect van het gebruik van trombocytenaggregatieremmers of 
anticoagulantia op het risico van OKG. 161 
 
De belangrijkste beperking van deze studie is het geringe aantal gevallen van OKG en het 
kleine aantal gebruikers van een aantal klassen van anthitrombotica die ons niet toelaat 
om eventuele kleine effecten in subgroepen te vinden. 
 
Er zijn steeds meer aanwijzingen in de literatuur over risicofactoren voor de progressie 
van OKG. De oogdruk is de meest bekende risicofactor van de progressie van OKG. 
Ondanks enkele goed uitgevoerde klinische studies blijven andere risicofactoren 
controversieel. In Hoofdstuk 4 hebben we gebruik gemaakt van verschillende statistische 
benaderingen om de risicofactoren die verband hebben met gezichtsveldprogressie in 
OKG te identificeren en bepaalden we de invloed van deze verschillende statistische 
benaderingen in de Groningen Longitudinal Glaucoma Study (GLGS), een prospectieve 
cohort studie in een klinische setting. We includeerden 221 ogen van 221 patiënten uit 
GLGS. Gemiddeld 7,2 betrouwbare gezichtsvelden waren beschikbaar na een gemiddelde 
follow-up van 5,4 jaar. Negenentachtig ogen vertoonden progressie. We vonden dat 
oogdruk, ziektestadium en leeftijd robuuste onafhankelijke risicofactoren waren voor 
progressie van gezichtsveldafwijkingen in OKG. 
 
Hoofdstuk 5 gaat in op een belangrijke klinische vraag: is bijziendheid (myopie) een 
risicofactor voor OKG? Myopie is al lange tijd geïdentificeerd als een risicofactor voor OKG 
maar er is onduidelijkheid met betrekking tot het bereik van de refractieve fout: hoewel 
sommige studies een associatie tussen OKG en zowel lage als hoge bijziendheid hebben 
gerapporteerd, hebben andere studies deze associatie alleen bij personen met hoge 
bijziendheid gevonden. Met als doel deze controverse op te lossen hebben wij een 
systematische review en meta-analyse uitgevoerd. Dertien studies met 48.161 personen 
voldeden aan de inclusie criteria; gegevens van 11 transversale populatiestudies werden 
opgenomen in de analyses. Het gepoolde relatieve risico van de associatie tussen myopie 
en glaucoom gebaseerd op 11 studies was 1,92 (95% CI 1,54 tot 2,38). 162 
 
Gebaseerd op zeven studies waren de gepoolde relatieve risico's van het verband tussen 
lage myopie (bijziendheid tot -3 dioptrie) en glaucoom en hoge myopie (-3 dioptrieën en 
meer bijziend) en glaucoom respectievelijk 1,65 (1,26-2,17) en 2,46 (1,93 tot en met 
3.15). Na het weglaten van studies die in belangrijke mate bijdragen aan de 
heterogeniteit, was het gepoolde relatieve risico 1,88 (1.60 tot 2.20) voor alle myopie en 
glaucoom en 1,77 (1,41 tot 2,23) voor lage myopie en glaucoom. Mensen met myopie 
hebben dus een verhoogd risico op het ontwikkelen van glaucoom, zelfs al bij lage 
myopie. 
 
In hoofdstuk 6 wordt de huidige stand van de kennis van de effecten van systemische 
medicatie op OKG beschreven. Systemische toediening van medicijnen binnen het 
lichaam kunnen een aanzienlijke stijging van de oogdruk veroorzaken en dus OKG. 
Corticosteroïden zijn de meest bekende en uitvoerig bestudeerde medicijnen met 
dergelijke kenmerken. Van anti-neoplastische middelen zoals docetaxel en paclitaxel is 
ook een oogdrukverhogend effect gerapporteerd. Andere medicijnen zoals 
koolzuuranhydraseremmers, bètablokkers, cannabinoïden en ginkgo biloba-extract 
verlagen de oogdruk en cholesterol-verlagende middelen lijken een beschermend effect 
te hebben bij OKG zonder de oogdruk te beïnvloeden – mogelijk hebben deze middelen 
dus een neuroprotectief effect bij OKG. Hier ligt een mogelijkheid voor de eerste klinsch-
toepasbare behandeling van OKG anders dan door middel van oogdrukverlaging, maar 
aanvullend bewijs lijkt aangewezen. Daarnaast hebben veel studies gesuggereerd dat 
oestrogenen een beschermende rol hebben bij OKG, maar meer onderzoek is nodig om 
dit effect te bevestigen. Het gebruik van trombocytenaggregatieremmers en 
anticoagulantia lijkt tot dusver niet geassocieerd te zijn met OKG. 163 
 
Acknowledgements 
 
I started working at the department of ophthalmology on the 1
st of May 2008. I 
remember my first day at work like yesterday. It has been a memorable time working 
with diverse people and I hereby take this opportunity to express my gratitude to all that 
have contributed to my pleasant time while working in this department. 
 
First and foremost, I will like to thank my supervisor/co-promotor. Dear Nomdo, I am 
very fortunate to have you as my supervisor. Your outstanding scientific thinking, 
excellent critical appraisal of scientific literature combined with an ingenious analytical 
insight was very resourceful to me in navigating my road through this project. Your 
philosophical approach of training PhD fellows and the sense of independency you abhor 
to your trainees are second to none. In addition, your talent in bringing out the best in 
people is priceless. 
 
Dear Anneke Hooymans, my promoter, your enthusiasm and humble beginning as an 
analyst has been an inspiration to me. Your broad insight, accessibility and words of 
encouragement after presentations are worth mentioning. 
 
Dear Hans Vingerling, my second promoter. Thank you for your readiness and willingness 
to be my second promoter. Your effort in securing grants for this project is much 
appreciated. Your broad intellectual reasoning and insight in leading discussions during 
my early research meetings in Rotterdam cannot be easily forgotten. 
 
I would like to thank all members of my manuscript committee, Prof. E. Hak, Prof. P.G.M. 
Luiten, Prof. C.A.B. Webers for taking their time to review and critically appraise this 
thesis. 
 164 
 
To my co-authors, Christiaan Wesselink, Margriet de Vries, Francisco Junoy Montolio, Dr. 
Wishal Ramdas, Dr. Rogier Müskens, Dr. Roger Wolfs, Prof. Bruno Stricker, Prof. Paulus de 
Jong, Prof. Albert Hofman, Dr. Richard Zegers, Prof. Hans Vingerling and Dr. Nomdo 
Jansonius your inputs and comments are invaluable. I also extend special thanks for the 
provision of indispensible medication data and collaboration to Prof. Bruno Stricker, 
ophthalmic data to Prof. Paulus de Jong and the Rotterdam Study as a whole to Prof. 
Albert Hofman. 
 
An ideal job to me is a job I would be looking forward to return to everyday. This is 
however impossible without warm-hearted and wonderful colleagues whom you can 
laugh and share life with. My colleagues both old and new and other members of the LEO 
legion: Christiaan, Kim, Else, Adit, Marielle, Margriet, Francisco, Tim, Wietse, Esther, 
Shao Chong and Lisanne created an atmosphere of fun and were always ready to give a 
helping hand. 
 
The list of persons that contributed to this project is endless. I would like to extend 
special thanks to Ella, Fenna, Stella, Albert, Joke, Wim and Luuk. Fenna, my appreciation 
seems incomplete without mentioning your effortless attitude towards helping me with 
articles. Your interest in others and your listening ears are also worthy to be mentioned. I 
am also greatful to Wishal Ramdas, Monika Czudowska, Lintje Ho and Ada Hooghart for 
their warm reception during my visits to Rotterdam. Ada Hooghart was very resourceful 
in helping me to retrieve missing data from patient files. Thanks Ada, I really appreciate 
your help. 
 
Finally Nelleke, the apple of my eyes, your unconditional love and support was the pillar I 
leaned on and without you the work described in this dissertation would not have been 
possible. 165 
 
About the author 
 
Michael Marcus grew up in Lagos, Nigeria. After completing his secondary school 
education, he studied chemistry at the University of Ibadan in Nigeria for a year and 
medicine at Obafemi Awolowo University in Nigeria for two years. In 1996, he relocated 
to the Netherlands and studied biomedical sciences at the Free University in Amsterdam 
and graduated in 2004. In 2005, he started a research masters at the University of 
Utrecht with a major in (clinical) epidemiology and obtained his master’s degree in 2007. 
In 2008, he started his PhD project presented in this thesis at the department of 
ophthalmology, University Medical Center Groningen under the supervision of Dr. Nomdo 
Jansonius in collaboration with the ophthalmic-epidemiology (Prof. Hans Vingerling) and 
the pharmaco-epidemiology (Prof. Bruno Stricker) group at the Department of 
Epidemiology, Erasmus Medical Center Rotterdam. From March 2012, Michael will 
commence his recently secured appointment as a postdoctoral research associate in 
statistics and epidemiology at the Roy Castle Lung Cancer Research, The University of 
Liverpool Cancer Research Centre, Liverpool, United Kingdom. 